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ABSTRACT
Sensitization to dog lipocalin allergens and other mammalian respiratory allergens is a
common cause of allergic disorders. However, surprisingly little is known about the
cellular  reactivity  to  these  agents.  As  the  activation  of  T  cells  is  a  key  event  in  allergic
sensitization, characterization of the human T cell responses to dog lipocalin allergens is an
important factor in elucidating the mechanisms by which they promote sensitization. This
is  also  a  prerequisite  for  the  development  of  new  modes  of  allergen-specific
immunotherapy.
The aim of this study was to analyze human CD4+ T cell responses to the dog lipocalin
allergens Can f 1 and Can f 4 in individuals with and without dog allergy. Moreover, the T
cell-stimulating regions (T cell epitopes) of Can f 4 were identified and their potential for
the development of peptide immunotherapy was assessed.
The epitope-containing peptides of the major dog lipocalin allergen Can f 1 were found
to  be  weakly  antigenic  on  human  T  cells in vitro.  They  exhibited  only  marginally  more
potent T cell stimulatory capacity than homologous peptides derived from a structurally
related human self-protein, tear lipocalin, as assessed by the functional characteristics of the
specific T cell lines in vitro. One possible mechanism accounting for the low antigenicity of
Can  f  1  is  that  its  epitopes  are  recognized  suboptimally  by  human  T  cells.  This  was
demonstrated by producing several peptide analogues that contained single amino acid
substitutions in comparison to the natural epitope. Stimulation of human T cells with these
analogues in vitro lead to stronger T cell responses. The low antigenicity/immunogenicity of
dog lipocalin allergens, potentially associated with suboptimal recognition by human T
cells, may be an important factor in explaining their allergenic capacity.
Determining the allergen-specific immune features distinguishing individuals with and
without allergy may help to understand the pathogenesis of allergy. Here, the frequency of
Can  f  4-specific  memory  CD4+  T  cells  was  found  to  be  substantially  higher  in  allergic
subjects than in those without allergy. These T cells exhibited robust immune polarization
towards the allergenic T-helper type 2 phenotype. In contrast, the allergen-specific memory
T  cell  responses  in  nonallergic  subjects  were  observed  to  be  much  weaker  and  of  a
protective, regulatory T cell phenotype.
The antigenicity of the T cell epitopes identified along the sequence of Can f 4 was found
to be associated with their promiscuous capacity to bind to a variety of commonly
expressed human leukocyte antigen (HLA) class II molecules. This feature is of special
importance in the development of peptide immunotherapy with a population-wide
coverage. The 19-mer Can f 446-64 peptide was recognized by 90% of the allergic subjects and
it  bound  strongly  to  several  HLA  class  II  molecules.  Therefore,  it  can  be  considered  as  a
candidate for the development of peptide immunotherapy of dog allergy.
National Library of Medicine Classification: QW 573, QW 900, QW 940, WF 150, WH 200
Medical  Subject  Headings:  Allergens;  Epitopes;  HLA  Antigens;  Hypersensitivity;  Immunotherapy;  T
lymphocytes
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TIIVISTELMÄ
Koiran lipokaliiniallergeenit, kuten muutkin eläinperäiset hengitystieallergeenit, ovat
yleisiä allergian aiheuttajia. T-soluilla on keskeinen rooli allergisen immuunivasteen
muodostumisessa, mutta syntyvästä T-soluvasteesta tiedetään kuitenkin varsin vähän.
Mallilla, jossa tutkitaan ihmisen T-soluvasteita koira-allergeeneja kohtaan, on mahdollista
tarkentaa allergisen immuunivasteen syntyyn liittyviä seikkoja ja toisaalta avata uusia
lähtökohtia allergian siedätyshoidon kehittämiseksi.
Väitöskirjatutkimuksen tavoitteena oli analysoida koira-allergisten ja terveiden
koehenkilöiden T-soluvasteita kahta koiran lipokaliiniallergeenia (Can f 1 ja Can f 4)
kohtaan. Lisäksi tutkimuksessa analysoitiin näiden allergeenien sisältämiä T-soluja
aktivoivia alueita eli T-soluepitooppeja ja arvioitiin niiden potentiaalia allergian
siedätyshoidossa.
Koiran pääallergeenin Can f 1:n havaittiin stimuloivan heikosti ihmisen T-soluja.
Havainto perustui siihen, että allergeenille spesifiset T-soluvasteet muistuttivat
voimakkuudeltaan ja laadultaan hyvin paljon vasteita, jotka olivat spesifisiä ihmisen
endogeeniselle kyynellipokaliinille. Sen aminohappoidentiteetti Can f 1:n kanssa on noin 60
%. Yhdelle Can f 1-allergeenin epitoopeista luotiin sarja peptidianalogeja, eli peptidejä,
jotka sisälsivät yhden aminohapon muutoksen epitoopin luonnolliseen rakenteeseen
nähden. Näillä peptideillä stimulointi johti T-soluvasteen voimistumiseen in vitro, mikä
viittaa siihen, että luonnollinen Can f 1-epitooppi tunnistetaan suboptimaalisesti. Tämä
löydös voi selittää allergeenin heikkoa kykyä aktivoida ihmisen T-soluja, mikä puolestaan
saattaa olla osasyynä niiden allergeenisuuteen.
Kun koira-allergisten ja terveiden kontrollihenkilöiden T-soluvasteita verrattiin,
allergisilla havaittiin kahdeksan kertaa enemmän allergeenispesifisiä T-muistisoluja
terveisiin nähden. Lisäksi allergisten potilaiden T-soluvaste oli voimakkaampi ja
merkitsevästi enemmän polarisoitunut allergiselle immuunivasteelle ominaisen Th2-tyypin
suuntaan. Terveiden koehenkilöiden soluvasteissa oli puolestaan havaittavissa piirteitä
immuunivastetta vaimentavasta regulatoristen T-solujen aktivaatiosta.
HLA-molekyylit ovat immuunijärjestelmän antigeeneja esitteleviä rakenteita. Can f 4-
allergeenin sisältämien epitooppien kyky stimuloida T-soluja havaittiin liittyvän siihen, että
ne kykenivät sitoutumaan useaan erilaiseen HLA luokan II-molekyyliin. Tämä ominaisuus
on oleellisen tärkeä uudenlaisen allergian siedätyshoitomuodon, peptidi-immunoterapian
kehittämisessä. Erityisesti peptidi Can f 446-64 osoittautui tässä suhteessa lupaavaksi. Sille
spesifisiä T-soluja havaittiin 90 %:lla Can f 4-allergisista koehenkilöistä.
Yleinen Suomalainen asiasanasto: allergia; allergeenit; lymfosyytit; siedätyshoito
VIII
IX
Acknowledgements
This study was conducted at the Department of Clinical Microbiology, Institute of
Clinical Medicine, University of Eastern Finland during the years 2007-2014.
I wish to express my gratitude and respect to my supervisors, Docent Tuomas Virtanen,
M.D., Ph.D. and Docent Tuure Kinnunen, M.D., Ph.D. for enabling this work to be carried
out. I would like to thank Tuomas Virtanen for his knowledge and perspective not only in
the  field  of  immunology  but  also  in  life  in  general.  I  owe  my  deepest  gratitude  to  Tuure
Kinnunen for his unconditional dedication to the process and his outstanding expertise,
both practical and theoretical. I feel privileged for having been able to undertake my thesis
under your guidance.
I  want  to  express  my  thanks  to  all  the  former  and  current  members  of  the  allergy
research  group  co-authoring  the  original  publications.  I  am  especially  grateful  to  Anssi
Kailaanmäki, M.Sc. and Marja Rytkönen-Nissinen, Ph.D. for all of the advice and practical
help. Anssi, I appreciate your scientific knowledge mixed with the laid-back attitude, keep
it that way! I also express my sincere thanks to our collaborators: Antti Taivainen, M.D.,
Ph.D.  and  Jukka  Randell,  M.D,  Ph.D.  at  the  Department  of  Pulmonary  Diseases,  Kuopio
University Hospital,  Bernard Maillère,  Ph.D. at CEA-Saclay, France, Ale Närväinen, Ph.D.
at the Department of Chemistry, University of Eastern Finland and Professor Jorma Ilonen,
M.D.,  Ph.D.  at  the  Department  of  Clinical  Microbiology,  University  of  Eastern  Finland.  I
wish  to  thank  Virpi  Fisk  for  the  skillful  technical  assistance  throughout  the  project.  I
express my gratitude also to all the subjects participating in the study.
I want to thank all of the personnel of the Department of Clinical Microbiology. The time
spent in the coffee room was an excellent counterweight to science. Most importantly, I
wish  to  thank  Anne  Lammi,  M.D.,  Suvi  Parviainen,  M.Sc.,  Tyyne  Viisanen,  M.Sc.  and
Emmi-Leena  Ihantola,  M.Sc.  with  whom  I  had  the  privilege  of  sharing  the  “student
chambre”. I could not have finished my project without all the therapeutic discussions and
laughters.  I  am  especially  grateful  to  Anne  for  her  friendship  and  the  sincere  support
during both medical and scientific studies.
I  warmly thank the  official  reviewers  of  my thesis,  Docent  Petteri  Arstila,  M.D.,  Ph.D.,
and  Professor  Johannes  Savolainen,  M.D.,  Ph.D.,  for  their  constructive  criticism  and
valuable suggestions in reviewing this thesis. I also wish to thank Ewen MacDonald, Ph.D.,
for his careful revision of the language of the thesis.
I am deeply thankful to all my relatives for their support. I wish to especially thank my
parents  Riitta  and  Pauli  for  their  encouragements  to  pursue  my  academic  ambitions.  My
thanks  go  also  to  my  parents-in-law,  Marjatta  and  Veikko.  I  am  deeply  grateful  to  my
brother  Lasse  and  brother-in-law  Juha  for  their  baby-sitting  services,  whenever  needed.  I
also want to thank my friends and their families I have the honor to have around me. I am
especially grateful to Mari Kilpivaara for her endless empathy and understanding.
Finally,  I  owe  me  deepest  love  and  thankfulness  to  my  husband  Pekka.  There  are  no
words to express the gratitude for everything you have done for me. The greatest thanks go
to my son Olavi. You have showed me the meaning of life.
This  study  was  financially  supported  by  Kuopio  University  Hospital,  The  Research
Foundation of the Pulmonary Diseases, the Respiratory Foundation of Kuopio, the Finnish-
Norwegian Medical Foundation, the Finnish Anti-Tuberculosis Foundation, the Maud
Kuistila Foundation and the Finnish Cultural Foundation.
Kuopio, December 2014
Aino Rönkä
X
XI
List of the original publications
This dissertation is based on the following original publications:
I Juntunen R, Liukko A, Taivainen A, Närväinen A, Kauppinen A, Nieminen A,
Rytkönen-Nissinen  M,  Saarelainen  S,  Maillère  B,  Virtanen  T  and  Kinnunen  T.
Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1. Mol
Immunol 46:3320-7, 2009.
II Liukko A, Kinnunen T, Rytkönen-Nissinen M, Kailaanmäki A, Randell J, Maillère
B and Virtanen T. Human CD4+ T cell responses to the dog major allergen Can f 1
and its human homologue tear lipocalin resemble each other. PLoS One 29:
9(5):e98461, 2014.
III Rönkä A, Kinnunen T, Goudet A, Rytkönen-Nissinen M, Sairanen J, Kailaanmäki
A,  Randell  J,  Maillère  B  and  Virtanen  T.  Characterization  of  human  memory  T
cell responses to the dog allergen Can f 4. Submitted.
The publications were adapted with the permission of the copyright owners.
XII
XIII
Contents
1 INTRODUCTION ................................................................................................................ 1
2 REVIEW OF THE LITERATURE ....................................................................................... 3
2.1 Allergy ............................................................................................................................. 3
2.1.1 Nomenclature ........................................................................................................... 3
2.1.2 Prevalence of allergy ............................................................................................... 4
2.1.3 Risk factors of allergy .............................................................................................. 4
2.2 Allergens ......................................................................................................................... 5
2.2.1 Nomenclature ........................................................................................................... 5
2.2.2 Lipocalin allergens ................................................................................................... 5
2.2.3 Dog lipocalin allergens ............................................................................................ 6
2.2.4 Allergenicity ............................................................................................................. 7
2.3 Introduction to allergic immune response ................................................................... 8
2.4 Antigen processing and presentation ........................................................................... 9
2.5 T cells ............................................................................................................................. 11
2.5.1 Development of CD4+ and CD8+ T cells ............................................................. 11
2.5.2 T cell activation ...................................................................................................... 12
2.5.3 CD4+ T cell differentiation .................................................................................... 14
2.5.4 CD4+ T cell homeostasis ........................................................................................ 15
2.5.5 Regulation of T cell response ................................................................................ 16
2.6 Treatment of allergy ..................................................................................................... 17
2.6.1 Symptom control.................................................................................................... 17
2.6.2 Allergen-specific immunotherapy........................................................................ 17
2.6.3 Hypoallergens ........................................................................................................ 18
2.6.4 Peptide immunotherapy ....................................................................................... 19
2.6.5 Altered peptide ligands in immunotherapy ........................................................ 20
3 AIMS OF THE STUDY ...................................................................................................... 21
4 MATERIALS AND METHODS ....................................................................................... 23
4.1 Subjects .......................................................................................................................... 23
4.2 Antigens ........................................................................................................................ 23
XIV
4.2.1 Recombinant antigens (I-III) ................................................................................. 23
4.2.2 Synthetic peptides (I-III) ........................................................................................ 23
4.3 Cell Separation .............................................................................................................. 24
4.3.1 Isolation of peripheral-blood mononuclear cells (I-III) ...................................... 24
4.3.2 Isolation of CD4+ T cell subsets with magnetic beads (II-III) ............................. 24
4.4 T cell cultures ................................................................................................................ 25
4.4.1 Culture medium (I-III) ........................................................................................... 25
4.4.2. Generation of T cell lines and clones (I-III) ......................................................... 25
4.5 Analyses of lymphocyte function................................................................................ 26
4.5.1 T cell proliferation assays (I-III) ............................................................................ 26
4.5.2 HLA class II restriction analyses (I, III) ................................................................ 27
4.5.3 Cytokine production assays (I-III) ........................................................................ 27
4.5.4 Flow-cytometric analyses (I-III) ............................................................................ 27
4.6 HLA class II peptide-binding assays .......................................................................... 28
4.7 Predictions of HLA class II binding sequence motifs ................................................ 28
4.8 Statistical analyses ........................................................................................................ 28
5 RESULTS ............................................................................................................................. 29
5.1 Human T cell response to the peptide p105-120 containing a T cell epitope of
dog Can f 1 (I) ..................................................................................................................... 29
5.1.1 Characteristics of the p105-120-specific T cell clones .......................................... 29
5.1.2 Recognition of p105-120 and its analogues by p105-120-specific T cell clones . 29
5.1.3 Stimulatory capacity of the heteroclitic analogues of p105-120 on polyclonal
T cells ............................................................................................................................... 30
5.1.4 Phenotype of the T cell lines specific to the analogues of p105-120 .................. 30
5.2 Analysis of human T cell responses to Can f 1 and its human homologue tear
lipocalin (II) ......................................................................................................................... 31
5.2.1 Frequencies of Can f 1 and tear lipocalin-specific T cells in peripheral blood . 31
5.2.2 Characteristics of the CD4+ T cell lines specific to Can f 1 and tear lipocalin .. 31
5.2.3 Binding of Can f 1, tear lipocalin and influenza hemagglutinin peptides to
HLA class II molecules ................................................................................................... 32
5.3 Comparison of dog lipocalin allergen-specific T cell responses between allergic
and nonallergic subjects ..................................................................................................... 33
5.3.1 Frequency and functional characteristics of Can f 4-specific memory CD4+
T cells in allergic and nonallergic subjects (III) ............................................................ 33
XV
5.3.2 Phenotype of Can f 1 and Can f 4-specific T cells in allergic and healthy
subjects (II, III) ................................................................................................................ 34
5.4 T cell epitopes of Can f 4 (III) ....................................................................................... 34
5.4.1 Epitope mapping ................................................................................................... 34
5.4.2 HLA-binding capacity of Can f 4 peptides .......................................................... 35
5.4.3 Co-localization of epitopes in lipocalin allergens and human tear lipocalin.... 35
6 DISCUSSION ..................................................................................................................... 37
6.1 Allergenicity of dog lipocalin allergens (I-II) ............................................................. 37
6.1.1 Suboptimal T cell recognition of lipocalin allergens by human T cells ............. 37
6.1.2 Human CD4+ T cell responses to the dog allergen Can f 1 and its human
homologue tear lipocalin resemble each other ............................................................ 38
6.1.3 The multiple layers of allergenicity ...................................................................... 39
6.2 T cell epitopes of Can f 4 (III) ....................................................................................... 40
6.2.1 The region aa 43-67 of Can f 4 is highly stimulatory on human CD4+ T cells .. 40
6.2.2 The promiscuous HLA-binding of the T cell epitopes of Can f 4 ...................... 41
6.2.3 Bioinformatic predictions of T cell epitopes of allergens ................................... 41
6.3 Dog allergen-specific T cell responses in individuals with and without allergy
(II-III) ................................................................................................................................... 42
6.3.1 Can f 4-specific memory CD4+ T cells exist at higher frequencies in allergic
subjects in comparison to nonallergic subjects ............................................................ 42
6.3.2 The expansion capacity of allergen-specific T cells in nonallergic subjects is
limited.............................................................................................................................. 42
6.4 Immunotherapeutic potential of Can f 1 and Can f 4 epitope-containing
peptides (I, III) .................................................................................................................... 44
6.4.1 Can f 446-64 – a candidate peptide for dog allergen-specific peptide
immunotherapy? ............................................................................................................ 44
6.4.2 Therapeutic potential of altered peptide ligands ................................................ 45
7 CONCLUSIONS ................................................................................................................. 47
8 REFERENCES ..................................................................................................................... 49
XVI
XVII
Abbreviations
AICD activation-induced cell death
APC antigen-presenting cell
APL altered peptide ligand
ASIT allergen-specific immunotherapy
CCR C-C chemokine receptor
CD cluster of differentiation
CDR complementary-determining region
CPM counts per minute
CRTH2 chemoattractant receptor-homologous molecule expressed on Th2 cells
CTLA cytotoxic T-lymphocyte-associated antigen
DC dendritic cell
EAACI European Academy of Allergy and Clinical Immunology
EBV Ebstein-Barr virus
ELISA enzyme-linked immunosorbent assay
ER endoplasmic reticulum
EC effective concentration
FACS flurescence-activated cell sorting
FCRI high-affinity IgE receptor
FITC fluorescein isothiocyanate
FOXP3 forkhead box P3
GITR glucocorticoid-induced THFR family related gene
HA hemagglutinin
HEL hen egg lysozyme
HLA human leukocyte antigen
HPLC high performance liquid chromatography
IFN interferon
IEDB Immune Epitope Database
Ig immunoglobulin
IL interleukin
ICAM intracellular adhesion molecule
ICOS inducible T cell costimulator
IC inhibitory concentration
IPEX immunodysregulation polyendocrinopathy enteropathy X-linked syndrome
kDa kilodalton
LPS lipopolysaccharide
LT lymphotoxin
mAb monoclonal antibody
MAIT mucosal associated invariant T cell
MFI mean fluorescence intensity
MHC major histocompatibility complex
NK natural killer
PBMC peripheral blood mononuclear cell
XVIII
PBS phosphate-buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PE-Cy5 phycoerythrin-cyanine 5
PHA phytohemagglutinin
PLA2 phospholipase A2
PMC perimedullary cortex
PPD purified protein derivative
ROR RAR-related orphan receptor
RPMI Roswell Park Memorial Institute
SCIT subcutaneous immunotherapy
SI stimulation index
SLIT sublingual immunotherapy
SMAC supramolecular activation cluster
SPT skin prick test
STAT signal transducer and activator of transcription
TAP transporter associated with antigen processing
T-bet T-box expressed in T cells
TCC T cell clone
TCL T cell line
TCR T cell receptor
TGF transforming growth factor
Th T helper
TL tear lipocalin
Treg T regulatory
1 Introduction
Allergy  is  a  hypersensitivity  disease  of  the  immune  system  against  innocuous
environmental substances, such as food, pollens and animal dust. At the cellular level, it is
characterized by the activation of T-helper type 2 cells (Th2), which leads to the production
of allergen-specific IgE antibodies by B cells and the release of inflammatory mediators that
eventually  cause  the  classical  allergic  symptoms  in  the  target  organ  (1).  Common  clinical
manifestations of allergy include allergic asthma, rhinitis, conjunctivitis, eczema and certain
gastrointestinal disorders.
The prevalence of allergic diseases has increased rapidly all around the world during
recent decades. Currently, about 10-20% of the world population has been estimated to
suffer from an allergic disorder (2). Allergies are chronic, often life-long diseases that affect
the quality of life and represent considerable economic burden on society (3). Although the
interactions of several genetic and environmental factors are known to contribute to the
development  of  allergy,  the  exact  cellular  mechanisms  involved  in  the  allergic  immune
response  are  unclear.  Moreover,  the  basis  of  allergenicity,  i.e.  the  capacity  of  allergens  to
induce the development of Th2 immunity, remains largely elusive.
Sensitization  to  dog  dander  is  a  common  cause  of  respiratory  allergy  (4).  Dog  allergens
disperse  efficiently  and  they  can  be  detected  in  the  indoor  air  in  domestic  houses  and
public  buildings,  such  as  schools  (5).  To  date,  six  dog  allergens,  Can  f  1-6,  have  been
identified from dog dander and urine. Four of them belong to the family of lipocalin
proteins that represents the largest group of mammalian inhalant allergens. The molecular
structure  and  IgE  reactivity  of  these  allergens  have  been  characterized  in  detail  (6),
however, little is known about the human T cell reactivity to these agents.
The treatment of allergy relies largely on palliative medication, such as antihistamines and
corticosteroids. The only disease modifying therapy currently available for the treatment of
allergy is allergen-specific immunotherapy (ASIT) during which progressive doses of
allergen extract are administered subcutaneously (7). The main drawbacks of the treatment
are its long duration (3-5 years) and the risk of severe IgE antibody-mediated side effects. A
promising way to improve the efficacy and safety of allergen-specific immunotherapy is to
administer small allergen-derived peptide fragments that are capable of activating specific
T cells but too short to induce IgE-mediated reactions. Mapping of these T cell activating
regions (T cell epitopes) of an allergen is a prerequisite for the development of new peptide
immunotherapy vaccines.
Previously, the T cell epitopes of only one dog allergen, Can f 1, have been characterized
(8).  An interesting feature  of  Can f  1  is  its  weak capacity  to  stimulate  the  proliferation of
peripheral blood mononuclear cells (PBMCs) from sensitized subjects in vitro (8,9).
Importantly, this characteristic is also shared by other lipocalin allergens, such as cow Bos d
2  (10,11),  horse  Equ  c  1  (12)  or  rat  Rat  n  1  (13).  Therefore,  the  weak  T  cell  stimulatory
capacity of lipocalins has been postulated to be a possible determinant of their allergenicity
(14).
2 The primary focus of this thesis was to assess the allergenic properties of the dog lipocalin
allergens Can f 1 and Can f 4 by characterizing the human T cell responses to these agents.
In addition, allergen-specific T cell responses between allergic and nonallergic individuals
were compared in order to clarify the immunological background of allergic sensitization
and tolerance. Finally, to extend the knowledge of dog allergen-specific human T cell
responses,  the  T  cell  epitopes  of  Can  f  4  were  mapped  and  their  potential  for  the
development of peptide-based allergen immunotherapy was analyzed.
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2.1 ALLERGY
2.1.1 Nomenclature
First coined by Austrian pediatrician Clemens von Pirquet in 1906, the term allergy (from
Greek allos ergos; altered reaction) initially referred to a general concept of changed immune
reactivity upon exposure to a foreign substance, an allergen (15). It was utilized to
distinguish “supersensitivity” reactions from protective immunity against infectious
agents. The term atopy was later introduced by Coca and Cooke to describe more
specifically the inherited tendency of developing immediate allergic symptoms (16). The
reaction was suggested to be mediated by “reagins” that were later recognized to belong to
the IgE-class of antibodies (17,18). In 1975, Coombs and Gell classified the different types of
hypersensitivities into four subgroups with the immediate, IgE-mediated allergy being
categorized as a type I hypersensitivity reaction (19). Today, the definition of allergy has
been broadened to cover also antibody-independent hypersensitivity reactions to an
allergen stimulus dominated by cellular interactions (20).
The clinical manifestations of the classical IgE-mediated allergy include allergic asthma,
rhinitis, conjunctivitis, certain gastrointestinal symptoms and eczema. Typically, atopic
individuals develop eczema and food allergies with gastrointestinal symptoms in
childhood, whereas respiratory symptoms, induced mostly by inhalant allergens, dominate
those appearing later in life (the so-called atopic march) (21). An example of the less
frequent, non-IgE-mediated allergy is allergic contact dermatitis, where the skin reaction is
directly  caused  by  the  activation  of  T  lymphocytes  (22).  Allergic  anaphylaxis,  an  acutely
developing multiple organ reaction, which causes characteristic symptoms of reduced
blood pressure and respiratory distress, is regarded as the most severe and potentially fatal
response  to  an  allergen  stimulus  (23).  The  term  was  first  proposed  by  Charles  Richet
already  in  1902  (24).  The  nomenclature  for  common  allergy-related  terms,  revised  by  the
World Allergy Organization in 2004 (20), is summarized in Table 1.
Table 1. Allergy nomenclature. Modified from (20) by permission of Macmillan Publishers
Ltd: Nature Reviews Immunology, copyright 2014.
Term Definition
hypersensitivity A state that causes objectively reproducible symptoms or signs. Initiated by exposure
to a defined stimulus that is tolerated by normal subjects.
allergy A hypersensitivity reaction initiated by immunological mechanisms. Can be antibody-
(usually the IgE isotype) or cell-mediated.
allergen An antigen causing allergic disease
atopy A personal and/or familial tendency, usually in childhood or adolescence, to become
sensitized and produce IgE antibodies in response to ordinary exposure to allergens,
and to develop typical symptoms such as asthma, rhinoconjunctivitis or eczema.
anaphylaxis A severe, life-threatening generalized or systemic hypersensitivity reaction.
IgE Immunoglobulin E, a subtype of immunoglobulins in mammals. Exists as a monomer
consisting of two heavy chains ( chain) and two light chains. Binding of IgE to FcRI
on mast cells triggers the degranulation of inflammatory mediators.
42.1.2 Prevalence of allergy
The global  prevalence  of  allergic  disorders  has  been reported to  be  around 10-20% (2).  In
western countries, the steepest increase in the prevalence took place towards the end of the
20th century  (25-27),  but  the  upward  trend  has  been  reported  to  be  levelling  off  during
recent years in some European countries (28,29). The overall prevalence, however,
continues to rise, mainly due to the increasing occurrence of allergy in developing countries
(2). In Finnish young men, the prevalence of asthma remained stable from 1926 to 1961 (30)
but has increased steadily since the 1960s (12-fold increase between the years 1966-2003) as
has the prevalence of allergic rhinitis (31). Recently, the prevalences estimated for common
allergic disorders in Finland were as follows: rhinitis 30%, asthma 8-10%, eczema 10-12%
and  conjunctivitis  15%  (32).  Pollen  and  animal  dust  are  the  most  common  sensitizers,
causing allergic symptoms in up to 20% of the population (32). Due to their common
occurrence and chronic nature, allergic diseases represent a considerably economic burden
on society, not only via direct health care costs but also through the loss of productivity (3).
2.1.3 Risk factors of allergy
Genetic factors contribute significantly to the development of allergic diseases. The atopic
phenotype has been associated with >100 susceptibility genes that regulate the
inflammatory pathways of both innate and adaptive immunities (33). Many of these genes
belong to the human leucocyte antigen (HLA) system or code for inflammatory signaling
molecules,  such  as  interleukins,  thus  they  are  directly  involved  in  the  pathogenesis  of
allergy. Other genes may contribute to the disease susceptibility indirectly, for example the
gene ADAM33, which is involved in the development of bronchial hyperresponsiveness in
asthmatic conditions (34).
The increasing incidence of allergic disorders, however, is clear evidence that also
environmental factors must play a role in the disease pathogenesis. This hypothesis is
further supported by the observation that the occurrence of allergic symptoms varies
largely in populations with similar genetic backgrounds but differing lifestyle (2). For
example, in the comparison of socio-economically distinct but genetically related
populations  of  East  and West  Germany,  marked differences  in  the  prevalences  of  allergic
disorders  were  demonstrated  after  the  fall  of  the  communist  system  (35).  Along  with  the
changes towards western lifestyle in the former East Germany, these differences were
reported to even out (36). The observation is in line with the hygiene hypothesis, according
to which the modern lifestyle is favorable for allergic development. Mechanistically, it has
been postulated to result from a lack of microbial exposure in the urban environment,
which may disrupt the normal tolerance development and the regulation of
hypersensitivity  of  the  immune  system  (37-40).  The  risk  factors  of  allergy  supporting  the
hygiene  hypothesis  from  the  epidemiological  point  of  view  are  listed  in  Table  2.  In
addition, there is evidence that two life-style factors, tobacco smoke (41) and obesity (42)
are associated with an increased risk of suffering allergic disorders.
5Table 2. Environmental risk factors associated with the risk of allergy/atopy.
Environmental factor Risk of allergy Reference
 
habitation urban rural/farm (29)
mode of delivery c-section vaginal (43)
postnatal diet breastfeeding (44)
family size & birth order older siblings (45)
daycare home daycare center (46)
medication childhood
antibiotics
(47)
2.2 ALLERGENS
2.2.1 Nomenclature
Most allergens are soluble proteins or glycoproteins. Allergens are defined as antigens that
are capable of binding specific IgE and inducing allergic symptoms in susceptible
individuals (20). To date, 796 allergens from mites, plants, animal dander, pollens, foods
and insects are listed in the official site for the systematic allergen nomenclature approved
by the World Health Organization and International Union of Immunological Societies
(IUIS; www.allergen.org, accessed 8/13/2014). In order to become officially listed as an
allergen, a set of biochemical criteria and demonstration of allergenic activity must be
fulfilled, including clearly defined molecular and structural properties and a demonstration
of IgE-binding capacity (48).
The systematic allergen nomenclature was originally developed in 1986 and later revised
in 1994 by the IUIS Subcommittee for Allergen Nomenclature (49,50). Purified allergens are
named using the first three letters of the taxonomic genus and the first letter of the species
followed by an Arabic number that indicates the chronological order of the allergen
purification (50,51). For example, Can f 1, the first dog allergen identified, is abbreviated
from the Linnean Canis familiaris.  The  polymorphism  of  allergens,  i.e.  isoallergens  and
isoforms (or variants) of allergens, is denoted with additional suffixes of a period followed
by  four  digits  in  the  nomenclature,  the  first  two  distinguishing  between  isoallergens  and
the last two between isoforms. Isoallergens, by definition, are multiple molecular forms of
an allergen in a single species that share a similar biological function, molecular size and an
amino acid identity of 67%, whereas the identity of isoforms of allergens is typically 90%
with only a limited number of amino acid substitutions (51). Moreover, a prefix letter in the
name  indicates  the  natural  (n),  synthetic  (s)  or  recombinant  (r)  origin  of  an  allergen,  for
example  rCan  f  1  (50).  Allergens  are  generally  called  major  or  minor  depending  on  the
percentage (greater or less than 50%, respectively) of clinically allergic subjects tested
showing specific IgE reactivity (50).
2.2.2 Lipocalin allergens
Lipocalins are a large family of small extracellular proteins that are capable of binding
small hydrophobic molecules such as odorants and pheromones (52). In addition, other
biochemical functions for lipocalins have been reported, for example, the non-specific
6endonuclease activity of human tear lipocalin and cow milk -lactoglobulin or the
immunomodulatory activity of placental protein 14 (53,54).
Most of the known mammalian inhalant allergens belong to the lipocalin family of
proteins (6,55-57). In addition, -lactoglobulin and four arthropodan allergens are lipocalins
(58). Mammalian lipocalin allergens can be found mainly in saliva, urine and dander (58).
The sequential length of these allergens is around 150-180 amino acids (aa), and they have a
molecular mass of 15-20 kDa and an acidic isoelectric point (6).
Lipocalins share a highly conserved three-dimensional structure with a -barrel core that
constitutes their ligand-binding site (58). They are also characterized by having one to three
structurally  conserved  regions  (SCRs  1-3)  in  their  primary  amino  acid  sequences.  The  N-
terminal SCR1, which contains the motif glycine-x-tryptophan (GxW), is considered as the
hallmark of the protein family since it is present in >90% of the known lipocalins. The SCR2
and 3 are characterized by the motifs threonine-aspartic acid-tyrosine-x-x-tyrosine
(TDYxxY)  and  arginine/lysine  (R/K),  respectively  (14).  Based  on  the  number  of  SCRs,
lipocalins are subdivided into two groups: kernel lipocalins contain all three motifs
whereas  outlier  lipocalins  contain  1-2  motifs  (58).  In  spite  of  the  structurally  conserved
regions and the conserved three-dimensional structure, the amino acid sequence identity
between  the  lipocalin  family  members  is  generally  low,  around  20-30%  (the  SIB  BLAST
network service, web.expasy.org/blast/; (6,14,59)). However, there are a few exceptions e.g.
the homology of dog Can f 1 with cat Fel d 7 (63%) and human tear lipocalin TL (57%) and
the  homology  of  dog  Can  f  6  with  cat  Fel  d  4  (67%).  These  pairs  have  also  exhibited  IgE
cross-reactivity (60,61).
2.2.3 Dog lipocalin allergens
Up  to  30%  of  individuals  suffering  from  atopic  conditions  are  sensitized  to  dog  dander
(4,62).  Four  of  the  six  dog  allergens  identified  to  date  (Can  f  1-6)  belong  to  the  lipocalin
protein family. The major dog allergen Can f 1 (45-70% of dog-allergic patients sensitized)
was  the  first  to  be  identified,  along  with  the  minor  dog  allergen  Can  f  2  (around  25%
sensitized)  (63,64).  The  two  more  recently  identified  dog  lipocalin  allergens  are  Can  f  4
(around 35-60%) (65,66) and Can f 6 (38%) (67). Dog lipocalin allergens are found in dog
dander or body secretions, such as saliva. The dog serum albumin Can f 3 (around 20-40%)
is  IgE  cross-reactive  with  several  other  mammalian  albumins  (68),  and  the  dog  prostatic
kallikrein Can f 5 (70%) exhibits IgE cross-reactivity with human prostate-specific antigen
(69). The characteristics of dog lipocalin allergens are summarized in Table 3.
Table 3. Dog lipocalin allergens.
Allergen Source Amino
acids
Molecular
weight
(kDa)
Sensitization
(%)
UniProtKB*
accession
No
Reference
Can f 1 Saliva, Dander 156 22-25 45-70 O18873 (63,64)
Can f 2 Saliva, Dander 162 22-27 25 O18874 (63,64)
Can f 4 Saliva, Dander 158 16-18 35-60 D7PBH4 (65,66)
Can f 6 Dander 175 20 38 E2QYS2 (67)
* UniProt Knowledgebase (www.uniprot.org; accessed 8/13/2014)
72.2.4 Allergenicity
Although allergenic proteins exhibit a diversity of molecular structures and biological
functions (51), they can be found in only about 5% of all structural protein families (PFam
database; (70)) suggesting that allergens possess special physicochemical or functional
features  that  contribute  to  their  allergenicity,  i.e.  the  capacity  of  inducing  a  Th2-biased
immune response in the host.
The specific physical properties of allergens may facilitate their presentation to the
immune system. The allergenicity of food allergens is potentiated by their heat and acid
stability as well as by their resistance to proteolytic degradation (71). Instead, the optimal
molecular weight and aerodynamics are critical for the efficient dispersion of respiratory
allergens (72). For some allergens, the natural enzymatic activity has been proved to be an
important factor in determining their allergenicity. For example, the major house dust mite
allergen Der  p  1  exhibits  cysteine  protease  activity,  which has  been shown to  facilitate  its
entry into mucous tissue by cleaving the intracellular junctions of epithelium cells (73) and
to disrupt the immune cell function by acting on lymphocyte surface receptors (74,75). For
others, the capacity to activate the innate immune system appears central. For instance, the
binding capacity of the peanut allergen Ara h 1 to the dendritic cell-specific ICAM-grabbing
non-integrin (DC-SIGN), a receptor on antigen-presenting dendritic cells, has been shown
to enhance allergen uptake and to stimulate the allergen-specific T cell response (76).
Not  only  the  allergen  proteins  but  also  other  components  in  the  allergen  source  can
possess properties promoting allergic sensitization. This type of an adjuvant effect has been
observed e.g. with diesel exhaust particles (77),  phytoprostanes derived from pollen grain
(78) and bacterial lipopolysaccharide (LPS) at low concentrations (79). Interestingly, higher
concentrations of LPS have been associated with conferring protection from allergic
sensitization (80).
Furthermore, the allergen concentration itself also appears to play a role in allergenicity.
For example, a prospective study analyzing the mouse Mus m 1 allergen concentrations in
the air demonstrated that development of specific antibodies peaked at the exposure level
of approximately 1.2 ng/m3 whereas  the  risk  of  becoming  IgE-positive  to  the  allergen
decreased at lower and higher concentrations of exposure (81). In line with this study, high-
dose exposure to the cat allergen Fel d 1 has been shown to favor the induction of tolerance
(82).
T  lymphocytes  are  central  players  in  allergy  (see  2.3)  and  the  T  cell  recognition  of
allergens is an important determinant of the subsequent response. Interestingly, in previous
studies investigating cellular immune response towards the allergens of the lipocalin
protein family, both human and murine responses have constantly been reported to be
weak (8-13). For example, the spleen cell response in BALB/c mice towards the cow allergen
Bos d 2 has been found to be significantly weaker than that mounted to a control antigen
hen  egg  lysozyme  (HEL)  (11).  In  addition,  the  activation  of  human  peripheral  blood  T
lymphocytes in response to dog Can f 1 has been observed to be significantly weaker than
that to the microbial streptokinase and a tubercle bacillus-derived preparation, purified
protein  derivative  (PPD)  (83).  Given  that  the  weak  T  cell  recognition  of  an  antigen  is  a
factor  favoring  the  deviation  of  T  cells  towards  the  allergenic  T-helper  type  2  phenotype
8(see 2.5.3; (84)), the low capacity of lipocalin allergens to stimulate specific T lymphocytes
may be one important determinant of their allergenicity.
2.3 INTRODUCTION TO ALLERGIC IMMUNE RESPONSE
The allergic sensitization process is characterized by the activation of allergen-specific T
lymphocytes  (Figure  1),  which  eventually  leads  to  the  immediate  and  late-phase
inflammatory responses, i.e., allergic inflammation.
Allergen-derived peptides are presented to T cells in lymph nodes by antigen-presenting
cells (APCs), such as dendritic cells (DCs). T cells recognize the peptides with their T cell
receptors (TCR), and become classically polarized into type 2 helper T cells (Th2 cells,  see
2.5.3).  These  cells  mediate  activation signals  to  B  lymphocytes  and other  cells  involved in
the allergic immune response via cell surface molecule interactions and the release of
proinflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-9 and IL-13 (85). The
production of IL-5 and IL-9 by Th2 cells activates the proliferation of eosinophils and mast
cells, respectively (85).
Importantly, B cells are activated through the release of the cytokines IL-4 and IL-13 and
the ligation of  specific  cell  surface  molecules  (CD40L on T cells  –  CD40 on B cells).  These
signals are the main inductors of the synthesis of the immunoglobulin (Ig)E antibody by B
cells. IgE is considered to be one of the major mediators of type I hypersensitivity reactions
underlying atopic conditions. Naïve B cells express only the IgM (or IgD) antibody isotypes
on their cell  surface. In order to produce IgE, activated B cells must undergo isotype class
switching.  In  this  process,  the  gene  coding  the  variable  region  of  an  IgM  antibody  with
specificity to the encountered allergen is recombined with the gene coding the constant
region of IgE (86). Once formed, the IgE molecules are secreted by the activated B cells and
bound by high-affinity Fc receptors (FcRI) on the surface of mast cells and basophils (87).
Upon  subsequent  allergen  exposure,  the  allergen  molecules  attach  directly  to  the  specific
FcRI-bound IgE-molecules, which leads to the cross-linking of the FcRI receptors. The
process  triggers  mast  cell  degranulation,  a  rapid  release  of  preformed  mediators,  such  as
prostaglandins, proteases and histamines, from the cytoplasmic vesicles of the cells (88).
These powerful mediators cause the classical allergic symptoms such as
bronchoconstriction, vasodilatation and plasma exudation within minutes.
The  late-phase  allergic  response  occurs  hours  after  the  exposure  to  the  allergen.  It  is
mediated by de novo synthesized mediators, including leukotrienes, prostaglandins and
interleukins, in mast cells. The mediators stimulate the growth and differentiation of
eosinophils and other inflammatory cells and alter vascular permeability in order to
facilitate inflammatory cell migration into the target tissues (85). A recurrent release of
proinflammatory cytokines and invasion of inflammatory cells may lead to a state of
chronic inflammation, which can eventually result in tissue remodeling such as thickening
of the smooth muscular wall,  mucous cell  hyperplasia and tissue fibrosis.  If  this occurs in
the asthmatic lung, the process may permanently reduce airway caliber (89).
9Figure 1. Allergic immune response. Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Immunology (90), copyright 2014.
2.4 ANTIGEN PROCESSING AND PRESENTATION
Antigen-derived peptide fragments are presented to T lymphocytes on antigen-presenting
cells in the context of cell surface major histocompatibility complex (MHC) molecules.
MHC molecules are transmembrane glycoproteins with short cytoplasmic domains which
are  normally  divided into  two subtypes  based on their  structure  and function.  The MHC
class I molecules consist of a larger (43 kDa), membrane-spanning -chain and a smaller (12
kDa) non-covalently bound  2-microglobulin (91). MHC class I molecules are expressed by
virtually  all  cells  in  the  body  with  the  exception  of  erythrocytes.  They  present  peptides
derived from cytosolic proteins to a subtype of T cells called CD8+ T cells. The MHC class II
molecules are formed by a noncovalent complex of - (34 kDa) and - (29 kDa) chains
which both span the  membrane,  and are  expressed on the  surface  of  specialized antigen-
presenting cells, such as dendritic cells, B cells, monocytes and thymic epithelial cells
(Figure  2).  These  cells  present  extracellular  peptides,  taken up by endocytosis,  to  CD4+ T
cells (91).
Before they can be presented on the cell surface, peptides must first be degraded from
proteins and then become associated with MHC molecules in the lumen of the endoplasmic
reticulum  (ER).  Peptides  forming  complexes  with  MHC  class  I  molecules  are  processed
from cytosolic proteins by proteasomes and transported subsequently to the ER lumen by a
transmembrane transporter associated with antigen processing (TAP). In the ER lumen, the
binding of a peptide to a partially folded MHC class I molecule attached to TAP completes
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the  MHC  folding  after  which  the  complex  is  translocated  to  the  cell  surface  (92).  In  the
formation of a peptide:MHC class II complex, an MHC class II molecule transported to the
ER is associated with a membrane protein known as the MHC class II-associated invariant
chain (Ii). A part of the chain, called CLIP, lies within the peptide-binding groove of MHC
class II  and prevents the molecule from binding to the peptide prematurely. The peptides
bound  by  MHC  class  II  molecules  are  degraded  from  exogenous  proteins  taken  up  by
endocytosis. The endosomes fuse with vesicles containing MHC II molecules to form an
MHC class II compartment, which becomes increasingly acidic and this in turn activates
proteases that degrade the endocytic proteins and the invariant chain. The CLIP fragment is
released from the peptide-binding groove in  a  reaction catalyzed by an MHC class  II-like
molecule called HLA-DM, which also helps with the binding of the antigenic peptide in the
groove. The complex is then ready to be presented on the cell surface (92).
The  peptide-binding  groove  on  both  MHC  class  I  and  II  molecules  consists  of  an  eight-
stranded -sheet floor and two antiparallel -helical walls. In an MHC class I molecule, the
ends  of  the  cleft  converge  and  the  space  can  accommodate  short  peptides  of  8-10  amino
acid residues. The cleft of an MHC class II molecule is open-ended and can hold longer
peptides, typically of 13-17 amino acid residues (93). The MHC molecule makes contact
with  the  amino  acid  residues  of  a  peptide  via  anchoring  cavities  in  the  peptide  binding
groove. The residues that point into the cavities are called anchor residues and the binding
pattern is referred to as the peptide-binding motif (94). In the peptide:MHC I complexes,
the anchor residues at the ends of the peptide are the major stabilizing contacts. In the
context  of  MHC  class  II  molecule,  the  anchor  residues  are  typically  scattered  along  the
peptide and the cleft usually binds three to five anchor residues. Most commonly, the
binding pockets of MHC class II  molecules are accommodated by four anchor residues at
positions  1,  4,  6  and  9  (starting  from  the  first  N-terminal  residue  of  the  motif),  with  the
residues 1 and 9 often being hydrophobic (91,95).
In  humans,  MHC  molecules  are  known  as  human  leukocyte  antigens  (HLA).  The  HLA
region is located on the chromosome six and contains more than 200 genes, many of which
are involved in antigen presentation or other related immune functions (94). The HLA
molecules expressed by an individual must be diverse to enable the presentation of the vast
diversity  of  antigens  encountered.  Therefore,  the  HLA system is  both polygenic,  meaning
that several different genes encode for the HLA molecules and polymorphic, meaning that
there are multiple allelic variants of a specific HLA gene at the population level. Three HLA
class  I  genes,  HLA-A,  -B  and  –C,  encode  for  the  HLA-I -chains (the  2-microglobulin is
coded by a gene outside the HLA locus), and three HLA-II genes, HLA-DR, -DP and –DQ,
encode for the HLA II - and -chains. In addition, the HLA-DR cluster often contains an
extra -chain gene.  Thus,  due to  polygeny,  up to  eight  different  HLA-II  molecules  can be
expressed on an antigen-presenting cell (94). The allelic polymorphism of the HLA system
is  largely  concentrated  on  the  parts  of  the  HLA  gene  sequences  that  encode  the  peptide
binding pockets of the binding groove. For example, to date, more than 800 allelic variants
of the most polymorphic HLA II locus, DRB, have been identified (91).
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2.5 T CELLS
T  cells  are  key  players  in  the  adaptive  immune  response.  They  are  characterized  by  the
expression of T cell  receptors (TCR) on their cell  surface (Figure 2).  TCRs are heterodimer
cell-surface  molecules  that  recognize  antigens  in  the  context  of  MHC molecules.  They are
typically composed of - and -chains that are disulfide-linked. Both of the chains consist of
two  segments:  an  amino-terminal,  membrane-distal  V  (variable)  region  and  a  carboxy-
terminal C (constant) region that passes through the cell surface membrane domain ending
in a short cytoplasmic segment (96).
T  cells  are  classically  divided  into  two  main  subclasses  based  on  their  phenotypic  and
functional characteristics. Cytotoxic T cells are  distinguished by the  expression of  the  CD8
molecule (CD8+ T cells) and helper T cells by the expression of the CD4 molecule (CD4+ T
cells) (97). The T cell receptors of CD8+ T cells recognize host cells that have been infected
with intracellular pathogens, such as viruses, since they now display the microbial peptide
in the context of their MHC class I molecules. CD8+ T cells act directly against the infected
host cells mainly by inducing apoptosis (98). In contrast, the T cell receptors of CD4+ T cells
recognize antigenic peptides of extracellular origin in the context of MHC class II molecules
on professional antigen-presenting cells (see 2.4). Stimulus via TCR induces CD4+ T cells to
provide  activation  and/or  inhibitory  signals  to  other  immune  cells,  such  as  B  cells,
eosinophils or macrophages.
In addition to CD4+ and CD8+ T cells,  other T cell  subtypes with unique functions have
been characterized. These include  T cells designated by their unique T cell receptor
composed  of  -  and  -chains,  natural  killer  T  cells  (NKT  cells)  and  mucosal associated
invariant T cells (MAIT). These cells are abundant in gut mucosa and possess characteristics
of both innate and adaptive immune system (99-101).
2.5.1 Development of CD4+ and CD8+ T cells
T lymphocytes  originate  from bone marrow stem cells,  but  they mature  in  thymus where
they are called thymocytes. Thymus is composed of two anatomically and functionally
distinct areas, medulla and cortex. Bone marrow-derived progenitors first occupy the
perimedullary cortex of thymus. During their development, thymocytes move on to the
subcapsular regions of the thymic cortex. Finally, thymocytes enter the medulla to be
ultimately released into the circulation (102).
Three major developmental stages, named the double-negative (DN), double-positive
(DP) and single-positive (SP) stages, dictate the T cell maturation (103). Each developmental
step is controlled by the unique regional microenvironment provided by specific thymic
stromal cells (102). The progenitors entering the thymus are CD4/CD8 double negative
(CD4-CD8-). During their migration towards the outer parts of the cortex, the formation of
the   T  cell  receptor  starts  with  the  rearrangement  of  the  TCR gene.  Concurrently,
thymocytes undergo extensive proliferative expansion.
A successful TCR gene rearrangement leads to the expression of the preTCR molecule,
an immature form of T cell  receptor that consists of a TCR chain and an invariant pre-
chain. The preTCR expression, in turn, induces the DP stage in the cells, i.e. the expression
of both CD4 and CD8 molecules on their surface. At this point, the rearrangement of the
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TCR gene takes place, and the cells start expressing mature TCRs (102). While migrating
back towards medulla, the DP thymocytes undergo positive selection, i.e. they try to
engage  a  self  peptide:MHC  complex  expressed  by  the  thymic  stromal  cells.  The  vast
majority, 90%, of the thymocytes fail and die by neglect. If the TCR of a thymocyte
recognizes a peptide bound to an MHC class I molecule, the cell produces a survival signal
and  downregulates  the  expression  of  CD4  becoming  single  positive  (SP)  for  the  CD8
expression. Respectively, a thymocyte expressing TCR that recognizes a peptide bound to
an MHC class II molecule becomes single positive for the CD4 expression. In addition to the
MHC ligation, the commitment of thymocytes to either the CD4 or the CD8 lineage seems
to require an optimal cytokine milieu (104).
Finally, the SP thymocytes undergo negative selection in the medullary region of thymus
rich with professional antigen-presenting cells that express MHC molecules with a variety
of peptides from self antigens. Those thymocytes that carry TCRs that bind too strongly to
self peptides, undergo apoptosis. As a result of positive and negative selections, cells with
low but significant avidity for self peptide:MHC ligands survive and ultimately exit the
thymus to join the circulating T cell repertoire (102,105).
2.5.2 T cell activation
Signaling  through  the  T  cell  receptor  is  critical  for  the  development,  activation  and
polarization  of  T  cells.  In  order  to  achieve  correct  T  cell  activation,  the  TCR  needs  to
recognize the structures of both the antigenic peptide and the MHC molecule presenting it
(96,106).  To ensure the recognition of the diversity of antigens encountered, an individual
must  harbor  a  vast  array  of  different  TCR  structures.  The  variability  is  achieved  by  the
somatic recombination of three types of gene segments of the TCR  and  chains, termed V
(variable), J (joining) and D (diversity). There are numerous copies of each segment. During
somatic recombination, the segments assemble randomly, producing a unique coding
sequence for the TCR of each lymphocyte (97). In the mouse, the process has been estimated
to result in a theoretical repertoire of >1015 unique   TCRs  (107).  Considering  that  both
TCR and MHC molecules also exhibit conformational flexibility at the peptide-binding site
(108),  virtually  almost  any  peptide  structure  can  be  recognized  by  the  TCRs  of  an
individual.
The cytoplasmic tail of the TCR molecule is too short to transmit an activation signal into
the cell. Instead, the intracellular downstream signaling is initiated by the nonpolymorphic
CD3 molecule complex associated constitutively with the T cell receptor. In the process, the
cytosolic domains of CD3 containing the immunoreceptor tyrosine-based activation motifs,
ITAMs, are phosphorylated by the lymphocyte-specific protein tyrosine kinase, LCK (109).
The following phosphorylation cascade initiated by LCK culminates in the activation of
several intracellular signaling routes that activate transcription factors (such as NF-B,
NFAT and AP-1) and eventually the genes related to the proliferation and differentiation of
T cells (110). In  addition,  the  coreceptor  molecules  CD8  and  CD4  on  T  cells  bind  to  the
nonpolymorphic  regions  of  the  membrane-proximal  domains  of  MHC  class  I  and  II
molecules, respectively. They are thought to enhance TCR triggering at least by stabilizing
the T cell receptor:peptide MHC (TCR:pMHC) interaction (111).
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Stimulation through the TCR:pMHC complex is not alone sufficient for the proper
activation of the T cell. In fact, it can result in T cell anergy, a hyporesponsive state where
the  T  cell  proliferation  and  effector  functions  are  inhibited  (112,113).  Therefore,  T  cells
require a secondary signal transmitted through a set of costimulatory receptors on the T cell
surface.  The  T  cell  activation  also  requires  a  third  signal  from  certain  cytokines,  such  as
interleukin  (IL)-12  or  interferon  (IFN)-I,  in  order  to  achieve  efficient  expansion  and  good
effector functions (114) (Figure 2).
The most important costimulatory receptor on the T cell surface is CD28, which not only
enhances the TCR-mediated activation of the cell but also induces the expression of other
costimulatory receptors (115). CD28 is ligated to the B7-1 (CD80) and B7-2 (CD86)
glycoproteins  on  APCs.  B7-2,  which  is  constitutively  expressed  on  APCs  at  low  levels,  is
upregulated before B7-1 and plays a more significant role in the priming of T cell activation.
Instead, B7-1 is virtually absent in non-activated APCs, but becomes highly expressed once
upregulated.  B7-1  has  been  speculated  to  play  more  of  an  inhibitory  role  in  the  T  cell
activation (116). In addition to a number of other effects, CD28 signaling increases
substantially  the  production  of  the  cytokine  IL-2,  which  enhances  T  cell  growth,
proliferation and differentiation (115). The binding of CD28 to its ligands leads to the up-
regulation of another molecule, cytotoxic T-lymphocyte-associated protein (CTLA)-4, on T
cells. CTLA-4 is also ligated to B7 molecules, but releases an inhibitory signal by blocking
the TCR downstream pathways and controlling T-cell adhesion and motility (117).
Numerous other recently identified molecules have also been shown to play costimulatory
roles  in  T  cell  activation.  These  include the  molecules  OX40,  inducible  T-cell  costimulator
(ICOS), 4-1BB and CD30 that are upregulated only upon TCR-mediated signaling (118).
Figure 2. TCR-mediated signaling and costimulation.
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CD4CD40L
CD3
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B7
CD40 MHC II
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During TCR signaling, the pMHC:TCR-complexes cluster in the contact site between the T
cell and APC. The contact area is called the immunological synapse (IS). It is formed by an
outer ring (peripheral supramolecular activation cluster, pSMAC) that mostly consists of
adhesion  molecules  and  a  central  area  (cSMAC)  enriched  in  TCRs  and  costimulatory
molecules. The immunological synapse is a dynamic structure that has been hypothesized
to sustain TCR signaling and focus the signal transmission and cytokine secretion between
the interacting cells (119).
In addition to receiving costimulatory signals, T cells also provide costimulatory help to
the other cells of adaptive immunity. For example, an important contact point between
activated T and B cells is the ligation of CD40L (CD154), a transiently expressed ligand on T
cells  upon  their  activation,  to  CD40,  which  is  required  for  the  isotype-switching  and  the
production of antibodies by B cells (120).
2.5.3 CD4+ T cell differentiation
T cells that have not encountered an antigen are called naïve T cells. Upon encountering an
antigen, CD4+ T cells become activated, undergo clonal expansion and differentiate into
effector T cells. Different effector T cell subtypes promote differential inflammatory
responses that are mediated mainly by the secretion of cytokines. The three major CD4+ T
cell subsets include the well-characterized Th1 and Th2 cells discovered almost 30 years
ago (121)  and the  more recently  identified Th17 (122)  cells.  Th1-type CD4+ T cells  are  the
main  inducers  of  the  macrophages  and  the  CD8+  T  cells  that  are  responsible  for  the
cytolytic immune response. They also provide support for the IgG isotype class switching
of B cells. IgG antibodies are effective in opsonizing pathogens, allowing their ingestion by
phagocytes. Therefore, the Th1-type CD4+ T cells play a major role in the protection against
intracellular pathogens and they participate in the elimination of cancerous cells (123). Th2-
type cells support the immune response against helminth infections and other parasites by
stimulating  eosinophils,  mast  cells  and  the  IgE-producing  B  cells  (123).  Th17  cells  are
involved  in  conferring  resistance  against  extracellular  bacteria  and  fungi  (122).  The  three
CD4+  T  cell  subtypes  are  also  involved  in  many  harmful  immune  responses,  such  as  the
tissue destruction seen in type 1 diabetes, multiple sclerosis or other autoimmune diseases
(Th1, Th17) as well as the pathogenesis of allergy (Th2, see 2.3) (124).
Several other CD4+ T cells populations, such as Th9 (125), Th22 (126) and follicular T
helper (TFH) cells (127), have also been recognized during recent years, although it is still a
matter of debate whether they represent unique CD4+ T cell lineages or simply reflect the
heterogeneity  of  the  existing  subtypes.  The  Th9  cells  have  been  shown  to  exert  a
proinflammatory effect in allergies and autoimmune diseases (125) whereas the Th22 cells
are thought to play a role in the regulation of inflammatory response, especially in the skin
(126). The follicular helper T cells are specialized in providing help in B cell activation in
lymphoid follicles (127). In addition, several T cell populations with regulatory functions
(see 2.5.5), are also subsets of CD4+ T cells. The growing number of CD4+ T cell subtypes,
along with the finding that some T cell populations exhibit the capacity to convert from one
type  into  another  (128),  highlights  the  plasticity  and  complexity  of  the  helper  T  cell
network.
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The  CD4+  T  cell  differentiation  is  regulated  by  all  the  elements  of  TCR  signaling  (see
2.5.2), i.e. the quality of the pMHC:TCR contact, costimulatory interactions and the
surrounding cytokine microenvironment. The strength of TCR signaling is mainly affected
by  the  antigen  dose,  its  affinity  and  the  duration  of  the  stimulation.  In  general,  weak
signaling appears to favor Th2 differentiation whereas stronger signaling promotes Th1
differentiation (84,129-131). The polarizing effect of the stimulation through costimulatory
receptors is unclear, however, at least the activation of intercellular adhesion molecules
(ICAM-1 and 2) has been postulated to contribute to Th1 polarization whereas the inducible
T cell costimulator (ICOS) activation seems to promote the Th2 phenotype (132-134).
The  cytokines  produced  by  antigen-presenting  cells  (mainly  dendritic  cells,  DCs)  are  a
major determinant of CD4+ T cell differentiation. Their commitment to express particular
cytokines is largely determined by the recognition of pathogens via their pattern
recognition receptors (PRRs) and by the signals they receive from other inflammatory cells.
Binding of the T cell surface molecule CD40L to CD40 on APCs induces the secretion of the
cytokines at the optimal time point (135).
With respect to the induction of Th1-type CD4+ T cells, the most important DC-derived
cytokine is IL-12. This cytokine activates the transcription factor T-bet, a key regulator of
the Th1 commitment via the STAT1 pathway and subsequently induces the production of
IFN- by  Th1  cells.  IL-12  also  inhibits  Th2  deviation  by  blocking  the  transcription  factor
GATA-3,  a  hallmark  of  the  Th2  phenotype  (124).  The  cytokine  IL-4,  instead,  is  the  main
activator of GATA-3 through STAT6 in Th2 cells. The initial source of IL-4 is not clear, but it
has been thought to be produced by basophils, macrophages, group 2 innate lymphoid cells
or by the T cells themselves (131,136). DCs appear to be incapable of producing IL-4 (123).
GATA-3  expression  upregulates  the  production  of  the  Th2  cytokines  IL-4,  IL-5  and  IL-13
and inhibits Th1 differentiation (124). The respective commitment pathways of the Th17
and iTreg cells (see also 2.5.5) are shown in Table 4.
Table 4. Hallmarks of CD4+ T cell subtypes (summarized from (124,135,137)).
Th1 Th2 Th17 iTreg
inductive cytokine IL-12 IL-4 TGF- (+ IL-6) TGF- (- IL-6)
STAT STAT1 STAT6 STAT3 STAT5
transcription factor T-bet GATA-3 ROR FOXP3
surface marker CXCR3 CCR4, CRTH2 CCR6, CD161 (CD25)
cytokines produced IFN, LT- IL-4, IL-5, IL-13 IL-17, IL-17F IL-10, TGF-
2.5.4 CD4+ T cell homeostasis
Continuous low-level contact with MHC molecule-bound self peptides in combination with
the exposure to IL-7 is needed for the survival of resting naïve T cells (114). In the quiescent
state,  they  mainly  reside  in  secondary  lymphoid  organs  and  are  characterized  by  the
expression  of  the  respective  homing  receptors  CCR7  and  L-selectin  (CD62L)  (138).  The
recognition of an antigenic peptide by naïve T cells induces their rapid proliferation and
differentiation into effector T cells (139). Effector T cells lose the expression of CCR7 and L-
selectin and start expressing receptors for inflammatory chemokines and homing molecules
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that allow their extravasation and entrance into the infected parenchymal tissue (138). After
an antigen challenge, the vast majority (>90%) of effector cells are destroyed (139).
Nonetheless,  a  fraction  of  them  do  survive  to  become  long-lived  effector  memory  T  cells
that reside in peripheral tissues and are capable of rapidly responding and exerting effector
functions (CCR7- Tem). In addition to effector memory T cells, an antigen challenge leads to
the development of another type of memory T cell population, central memory T cells.
These  cells  differ  from Tem in  that  they lack any effector  function and reside  in  secondary
lymphoid organs (CCR7+ Tcm) (140).  Their role is regarded as being important in retaining
the T cell memory, as they have a self-renewal capacity and are capable of evolving into Tem
cells. Both central and effector memory T cells are distinguished from naïve cells in terms of
their expression of the surface receptor CD45R. Memory T cells typically downregulate the
expression  of  CD45RA,  the  high  molecular  weight  isotype  of  the  protein  that  is  largely
expressed on naïve T cells, and start expressing its low molecular weight isotype, CD45RO,
that  facilitates  T  cell  activation  (141).  The  cytokine  IL-7  also  plays  a  key  role  in  the  long-
term survival and homeostasis of memory T cells. However, these cells appear to maintain
their numbers independently of contact with self peptide:MHC complexes (114).
2.5.5 Regulation of T cell response
The  deletion  of  self-reactive  T  cells  in  the  thymus  is  the  primary  way  of  establishing
tolerance to self structures (central tolerance; see 2.5.1). In the periphery, it is complemented
by a number of mechanisms that suppress harmful immune responses and regulate
inflammation, collectively referred to as peripheral tolerance (142). Ignorance is the state
where  the  triggering  point  of  T  cell  activation  is  not  reached,  for  example,  due  to  low
expression levels of a self antigen. Anergy refers to nonresponsiveness to an antigen e.g. it
can result from the lack of essential TCR costimulation. T cells may also become apoptotic
by repetitive TCR signaling, a phenomenon known as activation-induced cell death (AICD)
(142).
Regulatory T cells (Tregs) are the key mediators of peripheral tolerance. The two best
characterized Treg subgroups are the forkhead box P3 transcription factor-positive Tregs
(FOXP3+  Tregs)  and  the  T  regulatory  type  1  (Tr1)  cells. Both subgroups share common
properties, such as the expression of the inhibitory receptors cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) and glucocorticoid-induced TNFR family related gene
(GITR) and the ability to suppress effector T cell proliferation and cytokine production
(137,143).
FOXP3+ Tregs are characterized by the constant expression of the CD25 molecule,  the -
chain  of  the  IL-2  receptor.  They  can  originate  from  thymus  (natural  Tregs)  as  fully
functional  suppressor  T  cells  or  develop  in  the  periphery  from  naïve  CD4+  T  cells
(inducible or peripheral FOXP3+ Tregs). The natural and inducible FOXP3+ Tregs cannot be
clearly differentiated functionally from each other. In vitro, both subtypes exert their
suppressive effects primarily by contact-dependent inhibition (e.g. via costimulatory
ligands), but in vivo,  they  have  been  reported  also  to  induce  suppression  through  the
production of the cytokines TGF- or IL-10 (144).
The  second  major  subset  of  CD4+  Treg  cells,  the  Tr1  cells,  arises  in  the  periphery  from
naïve CD4+ T cells activated by tolerogenic antigen-presenting cells independently of
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FOXP3  and  in  the  presence  of  IL-10.  Despite  the  eager  attempts,  a  specific  marker  to
distinguish  the  human  Tr1  cells  from  other  CD4+  T  cell  subsets  remains  undefined  (145).
Importantly, once activated by the TCR ligation to a peptide:MHC complex present on an
antigen-presenting cell,  Tr1  cells  can mediate  their  suppressive  function against  cells  that
recognize other antigens via bystander activity, secreting large amounts of IL-10 as well as
transforming growth factor (TGF)-, but low levels of IL-2 (137,146,147).
Compromised Treg function has been demonstrated to have severe autoimmune-related
consequences. For example in mice, neonatal thymectomy that leads to the development of
multiple-tissue autoimmunity has been linked to CD4+CD25+ Treg cell deficiency (148). In
humans, a fatal autoimmune lymphoproliferative disorder termed the immune
dysregulation polyendocrinopathy enteropathy-X-linked (IPEX) syndrome is caused by
loss-of-function mutations in the FOXP3 gene (149). In addition to autoimmune diseases,
the regulatory T cells appear to play a role also in the pathogenesis and the treatment of
allergic diseases (see 2.6.2).
2.6 TREATMENT OF ALLERGY
2.6.1 Symptom control
The  symptoms  of  allergy  are  mainly  controlled  either  pharmaceutically  or  by  avoiding
exposure to the allergen. The symptomatic drugs include antihistamines, corticosteroids
and leucotriene receptor antagonists that provide immunosuppression relieving the
symptoms effectively. However, the use of symptomatic drugs in allergy is often long-
standing (even life-long), which can be a factor hampering patient adherence to the
treatment, e.g. due to the side effects or the cost of medication (150). Allergen avoidance is
considered as a necessity in the case of severe allergic reactions. However, complete
allergen avoidance is often problematic as allergens are present not only in domestic houses
but also in public places, such as schools and day care centers (5,151).
2.6.2 Allergen-specific immunotherapy
Allergen-specific immunotherapy (ASIT) refers to the practice of administering gradually
increasing quantities of an allergen product to an individual with an IgE-mediated allergic
disease in an attempt to ameliorate the symptoms associated with the exposure to the
causative  allergen  (7).  ASIT  is  the  only  disease-modifying  approach  available  for  the
treatment of allergy. The first immunotherapeutic trials were conducted on hay fever
patients  with  grass  pollen  extract  by  Leonard  Noon  and  John  Freeman  already  a  century
ago, establishing the therapy guidelines that are still largely pertinent today (152,153).
According to the EAACI Guidelines (7), allergen-specific immunotherapy is indicated for
the treatment of moderate to severe allergic rhinoconjunctivitis and mild to moderate
asthma  and  insect  venom  allergy,  but  not  for  allergic  eczema  or  food  allergies.  The
candidate patients for ASIT need to exhibit a laboratory-confirmed IgE sensitization to the
causative allergen and an exacerbation of the symptoms under allergen challenge. Factors
further supporting the decision to treat include poor response to pharmacological symptom
control, the development of adverse side effects to the medication and/or a frequent,
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unavoidable exposure to the sensitizing allergen. Absolute contraindications include a
serious immunological disease, a major cardiovascular disease, chronic infections and
severe  asthma.  Allergen-specific  immunotherapy  requires  a  period  of  three  to  five  years.
Currently,  two  types  of  ASIT  are  in  practice:  subcutaneous  immunotherapy  (SCIT)  and
sublingual immunotherapy (SLIT) (154). Both methods have been shown to be effective in
reducing symptoms and the use of medications (155,156), inducing long-term (~10 yrs)
tolerance (157,158) and preventing disease progression and new sensitizations (159).
The cellular mechanisms underlying the clinical efficacy of allergen-specific
immunotherapy are still largely unclear. Previously, it has been demonstrated that the
balance between the allergen-specific Th2-biased response and immune tolerance is altered
in allergic in comparison to nonallergic individuals (160,161). Therefore, one possibility is
that the therapeutic effects of ASIT are linked with the restoration of this balance. In fact,
several studies describing the cellular alterations during allergen immunotherapy have
demonstrated the deletion of allergen-specific effector Th2 cells or a downregulation of
their response (162,163). In addition, enhanced peripheral regulatory activity characterized
by an increase  in  the  levels  of  cytokines  IL-10  and TGF- (164,165)  and in  the  number  of
allergen-specific regulatory T cells (162,166) have been reported. Both FOXP3+ Tregs and
inducible Tr1 cells seem to play a role in the process (167).
Regulatory T cells have also been shown to mediate the protective effects of allergen-
specific immunotherapy to other immune cells.  For example, they are capable of inducing
the  production  of  IgG4  antibodies  by  B  cells  (168).  IgG4  antibodies  are  regarded  as
protective antibodies and their levels generally increase during successful ASIT. The
protective effects of IgG4 are thought to be mediated by blocking the IgE-binding of
allergens and the IgE-facilitated antigen presentation by B cells (169). Finally, regulatory T
cells have been shown to be able to modulate the function of dendritic cells (170,171).
2.6.3 Hypoallergens
The practice of allergen-specific immunotherapy is largely based on empirical experience
and may encounter several problems related to the efficacy and safety of the treatment. The
use of unstandardized allergen preparations may potentially lead to unpredictable adverse
reactions and even new allergic sensitizations (172-174). The long duration of the treatment
is a major reason for patient adherence problems (150). Most importantly, allergen-specific
immunotherapy is commonly associated with mild to moderate side-effects, but it also
involves  the  risk  of  developing  severe  systemic  reactions,  even  anaphylaxis  (154).  To
overcome these problems, it will be necessary to develope innovative allergen products.
An important cause of systemic side effects during allergen-specific immunotherapy is the
cross-linking  of  allergen-bound  IgE  on  the  FcRI-receptors  on  mast  cells  (see  2.3).  As  the
IgE binding of an allergen is dependent on its tertiary structure, conformational
modifications of the allergen represents one way to reduce this capacity while conserving
the T cell reactivity. Several techniques for engineering this type of hypoallergenic products
have been introduced. For example, the reduced IgE binding and basophil activation
together with stronger T cell stimulatory capacity have been associated with the
hypoallergenic  derivative  of  the  major  cat  allergen  Fel  d  1,  which  was  generated  by  the
duplication of selected T cell epitopes and disruption of the disulphide bonds within the
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protein (175). A similar effect was obtained with the introduction of point mutations in the
amino acid sequence of the major apple allergen Mal d 1 (176).  Moreover, treatment with
genetically fragmented or polymerized forms of the major birch allergen Bet v 1 has been
shown to be clinically well-tolerated and effective (177-179). Another promising approach
to establish allergen-specific T cell tolerance is to use allergen-derived peptide fragments
that are capable of stimulating T cells but too short for IgE-cross linking (see 2.6.4; (8,180)).
2.6.4 Peptide immunotherapy
The capability of allergen-derived peptides to induce tolerance to a larger allergen protein
was first described with a murine model of cat allergy by Briner et al. (181). Immunization
of  mice  with  the  peptides  derived  from  the  major  cat  allergen  Fel  d  1  resulted  in  a
decreased production of IL-2 and allergen-specific IgG. Thereafter, preclinical studies have
been  performed  with  various  allergens,  such  as  Der  p  2  (182),  Bet  v  1  (183),  and  the  bee
venom allergen phospholipase A2 (PLA2) (184). The two major cellular outcomes reported
by these studies have been the suppression of T cell proliferation and decreased production
of  the  cytokines  IL-4,  IL-13  and IFN-y.  In  addition,  a  decrease  in  the  allergen-specific  IgE
levels and an increase of the production of the protective IgG4 antibody were seen.
Clinical trials of peptide immunotherapy have been conducted with two allergens; cat Fel
d  1  and  bee  venom  allergen  PLA2.  Soon  after  the  first  murine  experiments  (181),  the
peptides  derived  from  the  major  cat  allergen  Fel  d  1  were  developed  into  a  vaccine
(ALLERVAX CAT) for clinical testing (185,186). The trials showed modest amelioration of
nasal  and lung symptoms,  however,  there  were  also  frequently  occurring immediate  side
effects,  evidence  that  the  27-mer  peptides  were  too  long  to  avoid  IgE-cross  linking.
Subsequently,  the  use  of  shorter  Fel  d  1-derived  peptides  (16-17  residues)  was  shown  to
suppress early phase reactions more effectively (187).  In the following years,  clinical trials
in patients with bee venom allergy were also conducted with peptides derived from PLA2.
In a study where five patients with systemic IgE-reactions to bee stings were treated with a
mixture of three immunodominant PLA2 peptides, three subjects developed clinical
tolerance, while the effect was reported to be suboptimal in the other two subjects (188).
One  of  the  putative  explanations  was  the  limited  HLA  coverage  of  the  selected  T  cell
epitopes in the vaccine. Indeed, another trial where the number of peptides was increased
to cover the whole PLA2 sequence, i.e. all possible T cell epitopes to match any given HLA-
genotype, achieved an improved outcome (189). Similarly, promising results have been
reported in recent clinical studies where a mixture of seven immunodominant Fel d 1 T cell
epitope-containing peptides of 13 to 17 amino acids was selected based on their wide HLA-
binding coverage (190,191). The trials also described persistent improvements of nasal and
ocular symptoms and good tolerability of the treatment (190,191). Collectively, these
studies  suggest  that  the  length  of  selected  peptides  and  the  genotype  variety  among
patients are factors that need to be considered for the safety of peptide immunotherapy.
When the cellular basis of the clinical outcomes was studied, the results were in line with
the preclinical  studies  showing the  suppression of  Th2-linked effector  functions  (187,189).
In addition, the enhanced production of IL-10 was reported (187,189). The IL-10 secretion in
peptide-immunotherapy is claimed to be attributable to the induction of Tr1-like cells (192).
They are thought to exert their therapeutic effects by linked epitope suppression, a process
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where the treatment with selected epitopes from an allergen resulted in the suppression of
responses to other epitopes within the same molecule (193). Another mechanism promoting
tolerance induction in peptide immunotherapy is associated with the administration of the
peptides,  as  delivering  of  peptides  in  a  soluble  form  without  an  adjuvant  may  establish
noninflammatory, tolerogenic conditions for T cell recognition (194).
2.6.5 Altered peptide ligands in immunotherapy
The therapeutic potential of structurally modified T cell epitopes (peptide analogues of
altered peptide ligands, APLs) in peptide immunotherapy has been evaluated in preclinical
models of infectious diseases (195), cancer immunology (196) and autoimmune diseases,
such as multiple sclerosis (197,198), type 1 diabetes (199,200) and arthritis (201-203). APLs
share  the  characteristics  of  the  native  peptide  sequence  but,  as  a  result  of  amino  acid
substitutions, deliver antagonistic, partial agonistic or superagonistic signals that may
induce  alterations  in  the  pMHC:TCR  binding  and  modify  the  subsequent  T  cell  response
(204-206). Stimulation with antagonistics/partial agonistic APLs has been demonstrated to
induce  suppression  of  T  cell  proliferation  (197,198)  and  deviation  towards  the  Th2
phenotype assessed by the production of cytokines (197,202) or the expression of
transcription factors T-bet and GATA3 (202). Instead, agonistic/superagonistic interactions
with APLs have generally increased the proliferation capacity of T cells and the production
of  IFN- (195,199,201).  The  regulatory  mechanisms  suggested  to  be  involved  in  the  APL-
mediated T cell activation include the induction of anergy (198,200) or apoptosis (203) and
the activation of regulatory T cells (197,203).
In the few studies that have evaluated the potential of APLs for use in the immunotherapy
of allergy in vitro, superagonistic (or heteroclitic) APLs have proved to be therapeutically
promising. They seem to be capable of inducing anergy and apoptosis in the responding T
cells and shifting the Th2-type response towards the Th1-type response (207-210).
Only a limited number of clinical trials have been conducted with altered peptide ligands.
In one study, treatment of multiple sclerosis (MS)-patients with an APL of a myelin basic
protein epitope achieved the desired cellular effects, the skewing of the T cell response
towards the Th2-phenotype. However, it unfortunately also led to immune hypersensitivity
reactions in the patients (211). In another MS study, the expansion of an APL-specific T cell
population was demonstrated, but it proved to be Th1-deviated and induced disease
exacerbations (212). No improvement in the clinical condition of the patients was observed
and  both  studies  were  prematurely  terminated  due  to  the  adverse  side  effects.  A  more
recent type 1 diabetes trial reported equally disappointing results; the treatment of type 1
diabetes patients with an APL of the B-chain of insulin did not result in any inhibition of
autoreactive  T  cells  or  any  improvement  of  the  clinical  status  of  the  patients  (213).  No
clinical trials with allergic patients have been conducted to date.
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3 Aims of the Study
The aims of the study were
 To analyze in vitro the antigenicity of a dominant epitope of the major dog lipocalin
allergen Can f 1 contained in the peptide p105-120 and to evaluate the potential of its
single amino acid modified analogues for allergen-specific immunotherapy (I).
 To compare in vitro the antigenicity of dog Can f 1 and its human homologue, tear
lipocalin (II).
 To compare in vitro dog  Can  f  1  and  Can  f  4-specific  memory  T  cell  responses
between allergic and nonallergic individuals (II-III).
 To  identify  the  human  T  cell  epitopes  of  the  dog  lipocalin  allergen  Can  f  4  and  to
assess in vitro their potential for use in peptide immunotherapy (III).
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4 Materials and Methods
4.1 SUBJECTS
Altogether 25 dog-allergic subjects (I-III) and 19 healthy dog-dust exposed controls (II-III)
were recruited into the studies. The allergic subjects were characterized at the Pulmonary
and Dermatology Clinics of Kuopio University Hospital (64). They were clinically atopic
and reported exacerbation of allergic symptoms upon dog-dust exposure. They exhibited
positive dog UniCAP results (FEIA; Pharmacia, Uppsala, Sweden; >0.7 kU/L) and positive
skin  prick  tests  (SPT;  3  mm)  with  a  commercial  dog  epithelial  extract  (ALK  Abellò,
Hørsholm,  Denmark).  The sensitization to  rCan f  1  (I-II)  was  verified by SPTs (64)  and to
rCan f 4 (III) by indirect ELISA (Rytkönen-Nissinen M, manuscript submitted). The control
subjects reported no medical history of atopy or allergic symptoms of any kind. The HLA
class II genotypes (DR/DQ) of the subjects were determined in the Clinical Laboratory of
Finnish Red Cross Blood Service (Helsinki, Finland) or in the Immunogenetics Laboratory
of University of Turku (Turku, Finland) by the PCR-SSO and PCR-SSP methods (214,215).
The study was approved by the Ethics Committee of the Kuopio University Hospital and
written informed consent was obtained from all participants.
4.2 ANTIGENS
4.2.1 Recombinant antigens (I-III)
The  recombinant  (r)  dog  allergens  rCan  f  1  (I)  and  rCan  f  4  (III)  were  produced  in Pichia
pastoris, and the IgE reactivity of the recombinant products was verified by immunoblotting
(60,64,66).
4.2.2 Synthetic peptides (I-III)
The Can f 1 peptide p105–120 (HGRQIRMAKLLGRDPE) and its 16-mer single amino acid
variants (I) were synthesized with PerSeptive 9050 Plus automated peptide synthesizer
(Millipore) with Fmoc strategy. The peptides were purified by HPLC (Shimadzu) with C18
reverse  phase  column  (Vydac)  and  verified  with  a  MALDI-TOF  mass  spectrometer
(Bruker)(8). All peptides were readily soluble in water.
The sequences of Can f 1 and tear lipocalin (II)  were aligned by the SIB BLAST network
service at the Swiss Institute of Bioinformatics (web.expasy.org/blast/). The Can f 1 peptides
pC1–pC9 and homologous tear lipocalin peptides pTL1–pTL9 ranging from 16 to 19 amino
acids were selected based on the verified T cell epitopes of Can f 1 (8) and the predictions of
HLA-DR-binding motifs in Can f 1 and TL (see 4.7). The peptides were synthesized at >80%
purity  by  GL  Biochem  Ltd.,  China.  For  the  induction  of  T  cell  lines  (TCLs),  the  peptides
were  arranged  in  pools,  each  of  the  six  pools  containing  three  Can  f  1  or  TL  peptides  as
follows: pC1+pC4+pC7, pC2+pC5+pC8, pC3+pC6+pC9, pTL1+pTL4+pTL7,
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pTL2+pTL5+pTL8, and pTL3+pTL6+pTL9. The influenza hemagglutinin (HA) peptide
(amino acids 306–318) (216), was also produced by GL Biochem Ltd.
The  48  16-mer  Can  f  4  peptides  (III)  overlapping  by  13  amino  acids  covering  the  entire
sequence of Can f 4 were synthesized at >80% purity by GL Biochem Ltd.
4.3 CELL SEPARATION
4.3.1 Isolation of peripheral-blood mononuclear cells (I-III)
Peripheral-blood mononuclear cells (PBMCs) were freshly purified from heparinized blood
by Ficoll-Paque Plus density gradient centrifugation (GE Healthcare Biosciences, Uppsala,
Sweden). Briefly, whole blood was first diluted 1:1 by phosphate-buffered saline (PBS) and
gently layered onto a Ficoll-Paque PLUS solution in a conical tube. After centrifugation
(Beckman Coulter Allegra X-12 Centrifuge), the PBMC layer was collected from the diluted
plasma/Ficoll interface, then centrifuged once more to reduce platelet/plasma protein
contamination and resuspended in the medium appropriate to the further application. The
cells  were  counted  after  Erythrocin  B  (Sigma-Aldrich  Chemie,  Steinheim,  Germany)
exclusion in a Bürker hemocytometer.
4.3.2 Isolation of CD4+ T cell subsets with magnetic beads (II-III)
Magnetic-activated cell sorting was used for the depletion of CD4+CD25high T cells from
PBMCs (II) with anti-CD25-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany)  and for  the  isolation of  memory (CD4+CD45RA-CD45RO+)  T  cells  from PBMCs
(III) by the depletion of non-CD4+ T cells and naïve CD4+ T cells using a cocktail of biotin-
conjugated antibodies against CD8, CD14, CD16, CD19, CD36, CD45RA, CD56, CD123,
TCR	 and  Glycophorin  A  with  magnetic  anti-biotin  beads  (Miltenyi  Biotec,  Bergisch
Gladbach, Germany).
Briefly, the freshly isolated PBMCs were first labelled with the specific antibodies and
magnetic  beads.  After  washing,  the  cells  were  passed  through  a  column  placed  in  a
magnetic field. The magnetically labeled cells were retained in the column. The unlabeled
cells passing through the column were collected and washed for further use. To verify the
purity of the isolation, a fraction of the collected cells was analyzed simultaneously in
parallel  with  unseparated  PBMCs  in  a  BD  FACSCanto  II  flow  cytometer  (see  4.5.4)  after
staining with anti-CD4-fluorescein isothiocyanate (FITC) and anti-CD25-phycoerythrin (PE)
in  study  II  and  anti-CD4-FITC,  anti-CD45RA-APC  and  anti-CD45RO-  phycoerythrin-Cy7
(PE-Cy7)  in  study  III  (all  from  BD  Biosciences,  San  Jose,  CA).  The  mean  purity  of  the
memory CD4+ T cells (III)  was routinely >97%. The cells retained in the column (III)  were
used as antigen-presenting cells after irradiation (3000 rad).
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4.4 T CELL CULTURES
4.4.1 Culture medium (I-III)
The complete culture medium RPMI 1640, supplemented with 2 mM L-glutamine, 20 μM 2-
mercaptoethanol, 1 mM sodium pyruvate, nonessential amino acids, 100 IU/ml penicillin,
100  μg/ml  streptomycin,  10  mM  HEPES  (all  from  Lonza,  Verviers,  Belgium)  and  5%
inactivated human AB serum (Sigma–Aldrich, St. Louis, MO), was used for culturing T cell
clones and lines.
4.4.2. Generation of T cell lines and clones (I-III)
For the generation of long-term T cell lines, freshly isolated PBMCs (I), those depleted of
CD4+CD25high T cells  (II)  or  purified CD4+CD45RO+ T cells  (III)  were  seeded in  96-well
round-bottomed plates (Corning Scientific) in a 150-200 μl volume of complete medium
with
Study I Can f 1 peptide p105-120 or its analogues (2 × 105 PBMCs per well, 20 wells
per peptide at 5 μg/ml)
Study II pooled (see 4.2.2) Can f 1 or TL peptides or the HA peptide (105 PBMCs per
well, 30 wells per pool, each peptide at 2 μM)
Study III rCan f 4 (5 x 104 cells per well; 60-90 wells per subject; 10 μg/ml of rCan f 4)
Wells with 1 μM of PPD served as a positive control (II, III). The TCLs were maintained in
the complete medium supplemented with 10-20 IU/ml of IL-2 until the split well analysis.
In  studies  I  and III,  the  cultures  were  restimulated once  before  the  analysis  with  1.5  ×  105
autologous -irradiated (3000 RAD) PBMCs together with 5 μg/ml of the peptides (I) or 10
μg/ml of rCan f 4 (III).
The antigen specificity of the cultures was tested on day 10 (II) or 20 (I, III) by measuring
their proliferation with the split well assay. First, half of the cells in each well were split into
two new daughter plates and stimulated with or without the antigens together with
autologous -irradiated (3000 rad) PBMCs (5 × 104 per well) as antigen-presenting cells.
After  an  incubation  period  of  72  h,  [3H]thymidine  was  added  (1  μCi  per  well;  GE
Healthcare, Little Chalfont, UK), and after an additional 16 h, the cells were harvested onto
glass  fiber  filters  (Wallac,  Turku,  Finland).  The  radionuclide  uptake  of  the  cultures  was
measured by scintillation counting (Wallac Micro Beta 1540). The results were expressed as
counts  per  minute  (CPM).  Antigen-specific  proliferation  was  defined  based  on  the
stimulation indices (SI;  CPM in the presence of antigen divided by CPM in the absence of
antigen) and CPM differences between stimulated and unstimulated wells (
CPM).
Criteria for positive cultures:
Study I SI>2
Study II 
CPM>2000 and SI>2
Study III 
CPM>1000 and SI>2
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Positive cultures were next restimulated in 48-well plates with the specific antigens,
autologous -irradiated PBMCs (106/well)  and  25-50  IU/ml  of  IL-2.  Thereafter,  half  of  the
culture medium was replaced with fresh medium supplemented with IL-2 every 2–3 days
during  the  14-day  culture  until  they  were  used  in  the  proliferation  assays.  As  the  TCLs
established in study II were induced with peptide pools, they were tested after the 14-day
culture with each of the three individual peptides in the pool at 10 μM (2.5 × 104 T cells with
5 × 104 autologous -irradiated PBMCs as APCs) to determine the peptide specificity. TCLs
showing a peptide-specific response (
CPM>2000, SI>2) were then restimulated once more
with the individual peptide at 2μM and 1.5 × 105 autologous -irradiated (3000 RAD)
PBMCs before proliferation assays.
The T cell clones 2C9 and 5G2 (I) were isolated from two Can f 1 p105-120-specific T cell
lines from a dog-allergic patient by the limiting dilution method basically as previously
described (8,10).  PBMCs were cultivated on 12-well plates at a density of 6 x 106 cells per
well in complete culture medium in the presence of 10 μg/ml of p105-120. On day 6, human
IL-2  was  added  at  a  final  concentration  of  5  IU/ml.  On  day  9,  the  IL-2  concentration  was
optimized to 20 IU/ml. On day 14, the cells were restimulated with p105-120 on 12-well
plates  at  a  density  of  3  x  106 cells  per  well  together  with  6  x  106 -irradiated (3000 rad)
autologous PBMCs. The restimulation was completed as described above. The T cell clones
were  isolated  from  rCan  f  1-specific  T  cell  lines  by  the  limiting  dilution  method.
Specifically, T cells were seeded out into wells of round-bottomed 96-well plates containing
allogenic -irradiated (6000 rad) PBMCs as feeder cells (2-3 x 105 cells/well), PHA (1 μg/ml)
and recombinant IL-2. The cultures were supplied with fresh medium and IL-2 (25 IU/ml)
at  2-3  day  intervals,  and  on  day  7  with  fresh  feeder  cells  (2-3  x  105 cells/well) and IL-2.
When growth became visible (on days 12-20), the reactivity of the growing clones to p105-
120 was tested in the thymidine incorporation assay (see above). The clonality of the T cell
clones  was  verified  by  PCR  using  a  panel  of  TCR  V subfamily-specific  primers,  as
described previously (217).  The TCR V usage of the clones was V8 for 2C9 and V4 for
5G2.
4.5 ANALYSES OF LYMPHOCYTE FUNCTION
4.5.1 T cell proliferation assays (I-III)
The T cell proliferation assays were set up in 96-well round-bottomed plates in triplicates or
duplicates for the T cell clones (I) and T cell lines (I-III), respectively. After a 72h incubation
of 2.5 × 104 T  cells  with  5  ×  104 autologous -irradiated PBMCs with and without the
respective antigen up to five 10-fold dilutions, the proliferation of the T cells was assessed
by [3H]thymidine incorporation (see 4.4.2). Dose-response curves were generated for each
TCC (I)  and TCL (I-III)  to  determine the  concentration of  the  peptide  needed to  induce a
half-maximal proliferative response (effective concentration 50, EC50) as an indicator of the
functional TCR avidity. The frequencies of antigen-specific T cells (II, III) were estimated by
dividing the number of antigen-specific TCLs in the proliferation assays by the number of
cells seeded per subject, assuming that each of them represented a monoclonal expansion of
a specific CD4+ T cell.
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The Can f  4  epitope mapping (III)  was  conducted by stimulating rCan f  4-specific  TCLs
with 48 overlapping 16-mer Can f 4 peptides (5 μg/ml) in duplicate wells. Wells containing
PHA  (1  μg/ml)  and  those  without  stimulant  were  included  as  positive  and  negative
controls. A proliferation response of SI>2 to at least two adjacent peptides was regarded as
specific.
4.5.2 HLA class II restriction analyses (I, III)
The HLA class II restriction of the TCCs (I) and TCLs (III) was determined by assessing the
capabiliity of monoclonal antibodies (mAbs) specific for HLA-DR (L243), DP (B7/21) or DQ
(SPVL3) to inhibit the peptide-specific proliferative responses of the cultures in vitro. 5 x 104
APCs were first incubated in duplicate for 1 h with 10 μg/ml of the antibodies. Next, 2.5 x
104 T cells together with 10 μg/ml of the specific peptide were added to the wells. Inhibition
of the proliferative response by at least 50% in the [3H]thymidine incorporation test was
considered statistically significant. In addition, individual restricting alleles were
determined by using allogenic, partially HLA-matched PBMCs and/or EBV-transformed B
lymphoblastoid cell lines with known HLA genotypes as APCs.
4.5.3 Cytokine production assays (I-III)
For the cytokine assays, T cell culture supernatants (100 μl/well) were collected from the 96-
well proliferation assay plates after a 72 h stimulation with a specific antigen. Supernatants
from replicate test wells were pooled and stored at 70°C until analyzed. The production of
IL-4, IL-5, IFN-, IL-10 and IL-17 was measured by using the commercial Bioplex system (I;
Bio-Rad,  Hercules,  CA)  or  ELISA  kits  (II,III;  DuoSet;  R&D  Systems;  Minneapolis,  MN)
according to the manufacturers’ instructions. To assess the cytokine phenotypes of TCLs
(III), an IFN-/IL-5 ratio was calculated (Th1: >5; Th2: <0.01; Th0: 0.01-5).
4.5.4 Flow-cytometric analyses (I-III)
For  the  analysis  of  the  T  cell  receptor  V subtypes  expressed  by  the  TCLs  (I),  the  IOTest
Beta  Mark kit  (Immunotech,  Marseille,  France)  was  used according to  the  manufacturer’s
instructions  with a  BD FACSCanto II  flow cytometer,  as  previously  described (9).  Briefly,
the cells were incubated with anti-CD4-PE-Cy5 antibody together with 24 fluorochrome-
labeles anti-V antibodies (V1, V2, V3, V4, V5.1, V5.2, V5.3, V7.1, V7.2, V8,
9, V10, V11, V12, V13.1, V13.2, V14, V16, V17, V18, V20, V21.3, V22,
23),  washed twice  with  PBS and analyzed by flow cytometry In  the  test  kit,  three  TCR
-specific antibodies were combined in a single test. One antibody was conjugated to
FITC,  another  one  to  PE,  and  the  third  to  both  FITC  and  PE.  TCR  V expansions  were
considered  statistically  significant  when  more  than  10%  of  the  CD4+  T  cells  expressed  a
particular V subtype and the level of expression was at least two times greater than that
on PBMCs.
The expression of a panel of cell surface markers (CD45RO, CD45RA, CD62L, CCR7,
CD25, CTLA-4, CXCR3, CCR4 and CCR6) by TCLs (II, III) was analyzed by flow cytometry
using monoclonal antibodies labeled with PE, PE-Cy7 or allophycocyanin (APC; all from
BD Biosciences) or corresponding isotype control mAbs. The results were expressed as
mean fluorescence indices (MFI).
28
4.6 HLA CLASS II PEPTIDE-BINDING ASSAYS
A  panel  of  common  HLA-DR  (I-III)  and  HLA-DP4  (I-II)  molecules  was  first
immunopurified from homologous EBV cell lines by affinity chromatography using the
monomorphic  mAbs  L243  and  B7/21,  respectively.  The  binding  affinity  of  the  Can  f  1
peptide p105-120 and its analogues (I), Can f 1 peptides pC1-pC9 and TL peptides pTL1-
pTL9  (II),  and  the  peptides  covering  the  immunodominant  regions  of  Can  f  4  (III)  to  the
HLA molecules was assessed by competitive ELISA, as described elsewhere (218-220).
Briefly, the HLA molecules were incubated with different concentrations of the competitor
peptide and an appropriate biotinylated peptide, and the bound peptide was assessed in a
fluorescence assay. The concentration of the competitor peptide that prevented binding of
50% of the labeled peptide (IC50) was calculated. To assess the validity of independent
experiments, unlabeled forms of the biotinylated peptides were used as reference peptides.
The results were expressed as IC50 ratios (ratio between the IC50 value of the tested peptide
and that of the reference peptide) in order to take into account the disparity of the binding
sensitivity between different HLA molecules. Lower IC50 values correspond to higher
binding affinities. An IC50 ratio of < 20 was considered as strong binding affinity, IC50 ratio
between 20-100 as moderate binding affinity and IC50 ratio > 100 as low binding affinity in
these studies.
4.7 PREDICTIONS OF HLA CLASS II BINDING SEQUENCE MOTIFS
The HLA DR binding motifs of the Can f 1 and TL sequences (II) were predicted with the
ProPred program (http://www.imtech.res.in/raghava/propred; (221)) and the top 3%
binders were selected. The IEDB resource Consensus tool (222,223) was used for the HLA
DR, DP and DQ binding predictions for the sequence of Can f 4 (III). Alleles expressed by
the study population were included in the analysis and the top 3% percentile rank of each
loci were selected.
4.8 STATISTICAL ANALYSES
The statistical analyses were conducted using the commercial GraphPad Prism software
(Graphpad Software, San Diego, CA). The Mann-Whitney U test was used for the analysis
of differences in the T cell frequencies, proliferation responses, cytokine production and
surface marker expression between TCLs stimulated with different antigens (I-II)  or TCLs
obtained from different subject groups (II-III). The Fisher's exact test was used to assess the
distribution of TCLs into specific avidity (II) or cytokine phenotype categories (III), and to
analyze  the  association  between  the  atopic  status  of  the  donors  and  the  number  of  TCLs
obtained  (III).  The  Wilcoxon  signed  rank  test  was  used  to  evaluate  the  binding  affinity
between Can f 1 peptides and their TL homologues to a set of HLA molecules (II),  and to
compare the HLA-binding of the peptides covering the immunodominant regions of Can f
4 (III). p values of 0.05 or less were considered statistically significant.
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5 Results
5.1 HUMAN T CELL RESPONSE TO THE PEPTIDE P105-120 CONTAINING
A T CELL EPITOPE OF DOG CAN F 1 (I)
5.1.1 Characteristics of the p105-120-specific T cell clones
Prior to undertaking the analysis of the human CD4+ T cell responses to the peptide p105-
120 containing a dominant T cell epitope of Can f 1(8), two T cell clones (TCCs) specific to
the peptide, 2C9 and 5G2, were isolated from the T cell lines of a Can f 1-allergic individual
(HLA-DRB1*1101/1501 and DQB1*0301/0602). The characteristics of the TCCs were
assessed by measuring their proliferation, HLA-restriction and capability of secreting
cytokines. In the proliferation assays, the concentration of p105-120 needed to induce a half-
maximal response (EC50)  was  0.05  μM (corresponding to  0.1  μg/ml)  for  clone 2C9 and 1.3
μM  (2.4  μg/ml)  for  clone  5G2,  indicating  a  higher  functional  TCR  avidity  for  the  former
clone. Clone 2C9 was found to be restricted by HLA-DQB1*0602 (I,  Fig. 1).  The restricting
locus  of  clone 5G2 was HLA-DR (I,  Fig.  1),  but  the  restricting allele  could not  be  reliably
confirmed due to the weak proliferative capacity of the clone (data not shown). Both clones
secreted  high  levels  of  IL-5  and  IFN- upon  stimulation  with  p105-120.  Based  on  the
calculated IL-5/IFN-y ratios, clone 2C9 was regarded as Th2-biased (ratio >10) and clone
5G2 as Th0/Th2-biased (ratio ~5; I, Fig. 1).
5.1.2 Recognition of p105-120 and its analogues by p105-120-specific T cell clones
For the assessment of the antigenicity of p105-120 on human T cells, the Can f 1-specific T
cell clones were stimulated with p105-120 or its analogues (altered peptide ligands: APLs)
containing single amino acid substitutions as compared with the natural peptide.
For the generation of the peptide analogues, the core sequences of the T cell epitopes
recognized by the p105-120-specific clones were first determined. Based on the recognition
of a panel of alanine- (or serine-) substituted peptide analogues (I, Fig. 2), the epitope core
was mapped between the residues 113 and 118 for the clone 2C9 and the residues 107 and
115  for  the  clone  5G2.  The  result  with  the  DR-restricted  clone  5G2  coincided  with  the
bioinformatic (IEDB) prediction of potential HLA-DRB1*1101 binding motifs (aa 108-116
and aa 109-117). Surprisingly, the epitope core of the HLA-DQB1*0602-restricted clone 2C9
did not overlap with the predicted binding motifs for DQB1*0602 (aa 108-116 and aa 109-
117; IEDB, accessed 8/28/2014).
Next, additional peptide analogues were generated with conservative and semi
conservative amino acid substitutions between the residues 109-116 overlapping the
experimentally verified epitope cores of both TCCs. While some of the amino acid
substitutions  were  not  tolerated  by  the  clones  (e.g.  substitutions  for  K113  by  2C9  and
substitutions for R110 and A112 by 5G2; I, Fig. 3), a total of 4 and 10 heteroclitic (i.e. more
optimal  than  the  natural  peptide)  APLs  were  identified  for  the  clones  2C9  and  5G2,
respectively (I, Fig. 3). These APLs induced a stronger proliferative response and a 10-fold
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decrease in the EC50 values  in  comparison to  the  original  peptide  (I,  Fig.  4).  These  results
indicate that the natural Can f 1 peptide p105-120 is recognized suboptimally by human T
cells.
5.1.3 Stimulatory capacity of the heteroclitic analogues of p105-120 on polyclonal T cells
The stimulatory capacity of the Can f 1 peptide p105-120 and its heteroclitic analogues was
further  assessed  by  generating  long-term  TCLs  with  p105-120  and  five  of  its  most  potent
analogues (R110K, K113R, L114I, L115F and G116T; I, Fig. 4) from the PBMCs of six Can f 1-
allergic subjects with different HLA genotypes. Only a total of four T cell  lines specific to
the natural p105-120 peptide were obtained from two out of six Can f 1-allergic subjects (I,
Table 1). Instead, the heteroclitic APLs proved to be more potent than p105-120 in inducing
specific TCLs. R110K, K113R and G116T induced a total of 7 to 11 specific TCLs from five
different subjects. L115F was found to be the most potent APL, inducing significantly more
TCLs than the original peptide (19 vs. 4, respectively, p=0.002). One to eight L115F-specific
TCLs  were  obtained  per  subject  (I,  Table  1).  L114I  was  the  only  APL  to  induce  a  lower
number of specific TCLs (2) than the natural peptide.
Importantly, when the APL-induced TCLs were stimulated with p105-120, the majority, 31
of  the  46,  TCLs  recognized  the  natural  peptide.  However,  with  the  exception  of  2  TCLs,
none of the cross-reactive responses were of higher functional avidity than the response to
the peptide used in the induction of the TCLs (I,  Table 2).  Importantly, a total of 13 TCLs
cross-reactive with p105-120 were induced with the most stimulatory APL, L11F,
demonstrating that L115F could expand p105-120-reactive T cells more effectively than the
natural peptide itself (13 vs. 4, p=0.04).
Next, the binding capacities of p105-120 and the heteroclitic APLs to a panel of common
HLA-DR  and  DP  molecules  were  assessed  to  determine  the  role  of  HLA  binding  for  the
differential stimulatory capacities by the APLs. p105-120 was found to bind to several HLA
alleles (DRB1*0301, DRB1*1101, DRB1*1301, DRB4 and DRB5) with strong affinity (I, Table
4). Only minor alterations (less than 6-fold) in the IC50 ratios were observed in the binding
affinities of the APLs R110K, K113R, L114I, L115F and G116T as compared with p105-120.
L115F was found to  bind to  DRB4 with a  slightly  improved affinity  in  comparison to  the
natural peptide (a 12-fold difference). However, this finding is not sufficient to explain the
increased frequency of TCLs induced with L115F, since only one of the subjects (subject F)
expressed the DRB4 gene. The results emphasize the role of TCR recognition of the
peptides rather than that of HLA binding as the source for the stronger APL-specific T cell
responses.
5.1.4 Phenotype of the T cell lines specific to the analogues of p105-120
The  expression  of  the  TCR  V subtypes  of  the  p105-120  and  APL-specific  TCLs  was
analysed  by  flow  cytometry.  It  was  observed  that  the  TCLs  expressed  a  variety  of  V
subtypes, and a total of 13 out of 24 subtypes tested were expanded in at least one of the
TCLs (data not shown). These findings suggest that the T cell responses specific to p105-120
and the APLs are not restricted by a specific TCR V subtype.
Generally,  the  production  of  the  cytokines  IL-4,  IL-5,  IFN-,  IL-10,  IL-17  by  the  TCLs
induced  with  p105-120  was  very  weak,  and  only  a  tendency  was  seen  towards  a  slightly
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stronger  cytokine  secretion  in  the  APL-induced  TCLs  (p>0.05;  I,  Table  3).  IL-5  and  IFN-
were  the  predominant  cytokines  produced  by  all  TCLs.  IL-17  was  not  detected  in  the
supernatant  of  any  TCL.  The  TCLs  induced  with  K113R  and  L114I  were  observed  to  be
Th2-polarized with the predominant production of IL-5 and the TCLs induced with R110K,
L115F  and  G116T  appeared  to  be  of  the  Th0  phenotype  with  the  balanced  production  of
both  IL-5  and  IFN-.  In  all,  stimulation  with  the  APLs  did  not  result  in  a  significantly
different cytokine profile compared to the natural peptide.
5.2  ANALYSIS  OF  HUMAN  T  CELL  RESPONSES  TO  CAN  F  1  AND  ITS
HUMAN HOMOLOGUE TEAR LIPOCALIN (II)
5.2.1 Frequencies of Can f 1 and tear lipocalin-specific T cells in peripheral blood
In study II,  the antigenic properties of Can f 1 were assessed by generating T cell  cultures
from  14  Can  f  1-sensitized  and  15  healthy  subjects  with  nine  Can  f  1  peptides  (pC1-pC9)
containing dominant epitopes of the allergen (8). In parallel, T cell cultures were generated
with nine Can f 1-homologous peptides present along the sequence of human tear lipocalin
(TL; pTL1-pTL9). The immunodominant epitope of influenza hemagglutinin (HA; aa 306-
318)  served  as  a  microbial  control  peptide.  A  specific  expansion  to  at  least  one  Can  f  1
peptide was observed in the cultures of 13 subjects from both subject groups. On average,
1.85±0.32% and 1.47±0.31% of the cultures seeded per allergic and per nonallergic subject,
respectively, were found to be specific to one of the nine Can f 1 peptides tested (II, Fig. 1).
The respective figures upon stimulation with the nine homologous TL peptides were about
half lower, 0.74±0.17% and 0.84±0.23% per subject. The frequencies of the lipocalin-specific
TCLs, however, clearly contrasted to those obtained upon stimulation with the influenza
HA peptide (12.68±10.98% per allergic and 8.60±13.37% per nonallergic subject; II, Fig. 1).
When 105 PBMCs were seeded per well, assuming that PBMCs contain approximately 30%
of CD4+ T cells and that each peptide-specific TCL represents a monoclonal expansion of an
antigen-specific CD4+ T cell, the average frequency of the Can f 1 peptide-specific T cells in
the circulating CD4+ T cell pool was estimated to be around 0.6 per 106 (0.0185 per 0.3 x 105)
CD4+  T  cells  in  allergic  subjects  and  around  0.5  per  106 in nonallergic subjects. The
respective frequencies of TL peptide-specific CD4+ T cells were estimated to be in the same
range, around 0.3 per 106 in both subject groups. In contrast, the value for the HA peptide-
specific TCLs was higher, around 3.5 per 106 CD4+ T cells per subject.
Collectively, the estimated frequency of T cells specific to Can f 1 was found to be low, in
the range of 1 per one million CD4+ T cells, or even lower in both allergic and nonallergic
subjects.  Importantly,  it  was  only  twice  higher  than  that  of  the  self-TL  peptide-specific  T
cells, but considerably lower than the frequency of the T cells specific to the influenza HA
peptide (II, Fig. 1).
5.2.2 Characteristics of the CD4+ T cell lines specific to Can f 1 and tear lipocalin
In  line  with  the  TCL  frequency  data  (see  5.2.1),  the  proliferative  responses  of  Can  f  1-
peptide-specific TCLs within allergic and nonallergic subject groups were found to be
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equally strong as the TL peptide-specific TCLs, but significantly weaker than those specific
to the influenza HA peptide (II, Fig. 2A), upon stimulation with the respective peptides. In
the analysis of the functional TCR avidities, the generated TCLs were categorized into
groups of  low (EC50>1.0 μM), intermediate (EC50 =  0.1–1.0  μM) and high avidity  (EC50<0.1
μM). Only up to 1.4% of Can f 1 and up to 3.6% of TL peptide-specific TCLs were of high
avidity (II, Fig. 2B), whereas a substantially greater proportion (25%) of HA peptide-specific
TCLs were of high avidity (II, Fig. 2B).
pC4 was the most frequently recognized Can f 1 peptide by the TCLs of both allergic and
nonallergic subjects (5.0±1.15% and 4.2±1.61%, respectively). Based on the IEDB binding
prediction, the sequence between residues 76 and 84 (YTAYEGQRV) contained in pC4 is
the motif that binds to HLA class II molecules in the most promiscuous way. This epitope
has  also  previously  been  demonstrated  to  be  capable  of  inducing  T  cell  responses  in
multiple Can f 1-allergic subjects (54). Within the TL peptides, it was found that pTL3 was
recognized the most frequently (1.89±0.57% and 4.2±0.68% in allergic and nonallergic
subjects, respectively).
In order to determine whether direct T cell cross-reactivity exists between homologous
Can f  1  and TL peptides,  the  peptide-specific  TCLs were  stimulated with the  counterpart
Can f  1  or  TL peptide.  It  was  found that  only  six  Can f  1  peptide-specific  TCLs (induced
with  pC1  or  pC4)  and  one  TL  peptide-specific  TCL  (induced  with  pTL4)  recognized  the
counterpart peptide in the proliferation assay. Five of the TCLs were obtained from allergic
subjects and two from nonallergic subjects (II, Fig. S2).
Both Can f  1  and TL peptide-specific  TCLs were  found to  exhibit  a  Th2-biased cytokine
phenotype with the predominant production of IL-4 and IL-5 and weak production of IFN-
 (II,  Fig.  3).  The phenomenon was stronger  within the  allergic  subjects  in  comparison to
the nonallergic subjects. However, no significant differences in the production of these
cytokines between the Can f 1 and TL peptide-specific TCLs were observed in either of the
subject  groups.  Instead,  the  Th1-bias  of  the  T  cell  responses  of  both  allergic  and  healthy
subjects to the HA peptide was obvious, as the HA peptide-specific TCLs produced
significantly more IFN- than the Can f 1 or TL peptide-specific TCLs. In accordance with
the cytokine data, the Th2-associated chemokine receptor CCR4 was found to be expressed
to a greater extent whereas that of the Th1-associated chemokine receptor CXCR3 was less
expressed  on  the  Can  f  1  and  TL  peptide-specific  TCLs  than  on  the  HA  peptide-specific
TCLs (II,  Figs 4 and S6).  The expression level of the surface molecules CD45RO, CD45RA,
CD62L, CCR7, CTLA-4, CCR4 and CCR6 did not differ in terms of the antigen specificity of
the TCLs.
Collectively, the results demonstrate that both the strength and phenotype of the T cell
responses  induced  with  Can  f  1  resemble  those  induced  with  the  self-lipocalin  TL  but
clearly differ from the T cell responses induced with the microbial antigen HA.
5.2.3 Binding of Can f 1, tear lipocalin and influenza hemagglutinin peptides to HLA
class II molecules
Differences  in  the  binding  affinities  of  antigenic  peptides  to  HLA  class  II  molecules  can
potentially affect their stimulatory capacity and the subsequent T cell response. To address
this  possibility,  the  binding  of  Can  f  1,  TL  and  HA  peptides  to  a  repertoire  of  common
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HLA-DR molecules was measured. The results were expressed as relative binding ratios
(IC50 ratios).
When  the  binding  of  Can  f  1  and  TL  peptides  by  individual  HLA-DR  molecules  was
assessed,  no  significant  differences  were  observed  between  them  (II,  Fig.  5).  When  the
binding  of  homologous  Can  f  1  and  TL  peptide  pairs  to  the  HLA  alleles  was  compared,
only  one Can f  1  peptide,  pC7,  was  found to  exhibit  a  significantly  higher  affinity  for  the
alleles than the counterpart peptide, pTL7. Interestingly, the binding affinity of one of the
TL peptides, pTL3, was also significantly higher than that of the counterpart peptide, pC3.
The HA peptide was observed to be bound with high affinity to five HLA-DR molecules,
which is a value not atypical for some of the Can f 1 or TL peptides (II,  Fig. 5).  When the
binding affinities of all HLA alleles were compared between the HA peptide and individual
lipocalin peptides, the HA peptide bound to HLA-DR significantly more strongly than one
of the Can f 1 peptides, pC9, and three of the TL peptides, pTL2, pTL8 and pTL9.
Taken together, these data suggest that the HLA-DR binding is an unlikely factor to
account  for  the  observed  differences  in  the  induction  and  stimulatory  capacities  of  T  cell
lines by Can f 1, TL or HA peptides.
5.3 COMPARISON OF DOG LIPOCALIN ALLERGEN-SPECIFIC T CELL
RESPONSES BETWEEN ALLERGIC AND NONALLERGIC SUBJECTS
5.3.1 Frequency and functional characteristics of Can f 4-specific memory CD4+ T cells in
allergic and nonallergic subjects (III)
The comparison of in vivo-induced allergen-specific T cell responses between allergic and
healthy subjects may help in elucidating the pathogenesis of allergy. In study III,  Can f 4-
specific T cell lines were induced by stimulating highly purified memory CD4+ T cells from
13 dog-allergic and 12 nonallergic subjects with recombinant Can f 4 protein. A variety of
HLA class II alleles were expressed by both allergic and healthy subjects (III, Table E1) and
the distribution of the alleles did not differ statistically between the subject groups.
Can f 4-specific memory TCLs were obtained from 12 out of 13 allergic subjects (92%, 86
TCLs)  but  only  from  3  out  of  12  nonallergic  subjects  (25%,  11  TCLs,  p=0.001).  The
frequencies  of  Can  f  4-specific  memory  CD4+T  cells  were  estimated  by  the  number  of
specific  cultures  obtained  per  seeded  memory  CD4+  T  cells  (3-4.5  x  106) per subject,
assuming that each of them represented a monoclonal T cell  growth. An 8-fold difference
was  observed  in  the  calculated  frequencies  of  Can  f  4-specific  memory  CD4+  T  cells
between the allergic and healthy subject groups (2.46±2.45 vs. 0.31±0.59 per 1 million
memory CD4+ T cells, respectively; III, Fig. 1A). Moreover, the functional avidity of Can f 4-
specific  memory  CD4+  TCLs  from  allergic  subjects,  as  assessed  by  EC50 values, was
observed  to  be  considerably  higher  than  that  of  TCLs  from  nonallergic  subjects,  (III,  Fig.
1B).
Collectively, the results demonstrate that allergic individuals harbour a higher frequency
of Can f 4-specific CD4+ T cells of memory origin and that these cells recognize the allergen
with higher avidity than the T cells of healthy subjects.
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5.3.2 Phenotype of Can f 1 and Can f 4-specific T cells in allergic and healthy subjects (II,
III)
The production of  the  cytokines  IL-4,  IL-5,  IFN-,  IL-10  and IL-17  by the  Can f  1  (II)  and
Can f  4-specific  (III)  TCLs from allergic  and nonallergic  subjects  was  compared.  The Th2-
type cytokines IL-4 and IL-5 were observed to be produced more efficiently by the Can f 1-
specific TCLs of allergic subjects than by their nonallergic counterparts (II, Fig. 3). A similar
finding was observed in study III, with Can f 4-specific memory TCLs from allergic subjects
producing more IL-4 and IL-5 than those from nonallergic individuals (III, Fig. 2A)
The production of IFN- or IL-10 by the Can f 1-specific T cells did not differ between the
allergic and nonallergic groups (II, Fig. 3). However, the Can f 4-specific memory TCLs of
nonallergic  subjects  were  observed to  secrete  more  IFN- and IL-10  than those  of  allergic
subjects (III,  Fig, 2A), indicating a possible Th1/Tr1 deviation of the in vivo-induced T cell
response  in  these  nonallergic  subjects.  When  each  Can  f  4-specific  TCL  was  categorized
phenotypically  by  calculating  an  IFN-/IL-5  ratio  (III,  Fig.  2B),  64%  of  the  TCLs  from
allergic subjects and 27% of those from healthy subjects were observed to represent the Th2
phenotype (p=0.03).  In  contrast,  only  4% of  the  TCLs from allergic  subjects  but  36% from
healthy subjects were Th1-biased (p=0.003). In line with the cytokine data, the expression of
the Th1-associated chemokine CXCR3 was lower in the Can f 4-specific memory TCLs from
allergic subjects (III, Fig. 2C). Moreover, the activation status of the Can f 4-specific TCLs, as
assessed by the expression of the IL-2 receptor alpha-chain (CD25), was found to be higher
in the TCLs from allergic subjects (III, Fig. 2C).
5.4 T CELL EPITOPES OF CAN F 4 (III)
5.4.1 Epitope mapping
In an attempt to identify the T cell epitope regions along the sequence of Can f 4, 88 specific
TCLs  obtained  with  the  allergen  protein  from  the  memory  CD4+  T  cells  of  12  (out  of  13)
allergic and 3 (out of 12) nonallergic subjects were stimulated with overlapping 16-mer Can
f 4 peptides. The epitope-containing regions recognized by the allergic subjects were found
to  be  scattered  throughout  the  allergen  sequence  (III,  Table  I  and  Table  E4  in  the  Online
Repository).  The  few  Can  f  4-specific  TCLs  obtained  from  subjects  without  allergy
recognized the same epitopes as the TCLs from allergic subjects, indicating that the T cells
of allergic and nonallergic subjects do not differ substantially in terms of their patterns of
epitope recognition. The average of 3.3±0.62 and 2.3±0.88 epitopes was recognized per
allergic and per nonallergic subject, respectively.
The  four  most  prevalently  recognized  Can  f  4  regions  were  located  between  amino  acids
(aa) 13-31, 43-67, 91-127 and 124-148 (III, Table I). These regions were recognized by the Can
f 4-specific TCLs of at least three subjects. They were also observed to be more stimulatory
than the  other  Can f  4  regions,  as  assessed by the  mean stimulatory indices  (46.4±66.5  vs.
29.6±27.6, p=0.007). The region aa 43-67 was found to be recognized most frequently, as the
peptides covering it stimulated TCLs from 10/11 (90%) of allergic and 1/3 (33%) of
nonallergic  subjects  (III,  Table  I).  Three  allergic  subjects  and  one  nonallergic  subject
harbored T cells  specific  to  this  region only.  The amino acid sequence shared by adjacent
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Can  f  4  peptides  able  to  stimulate  a  T  cell  line  was  defined  as  the  core  sequence  of  an
epitope region. The minimal core sequence of the most stimulatory region aa 43-67 was the
19-mer sequence PRLKMLFNFYVKVDGECVE (aa 46-64; III, Fig. 3).
Next, the HLA class II restriction elements of 34 Can f 4-specific TCLs from eight allergic
subjects  and  one  nonallergic  subject  were  analysed  (III,  Table  E5).  It  was  discovered  that
74% of the T cell responses were restricted by HLA-DR, 21% by HLA-DQ and 4% by HLA-
DP. Importantly, T cell responses to the four most stimulatory regions of Can f 4 were not
exclusively  restricted by either  HLA-DR,  -DP or  -DQ molecules.  A similar  variability  was
also observed in the analysis of allelic restrictions (III, Table E5). Collectively, the results
suggest that Can f 4 epitopes are presented by a wide array of HLA class II alleles.
5.4.2 HLA-binding capacity of Can f 4 peptides
Bioinformatic  predictions  of  the  HLA  class  II  peptide  binding  motifs  in  Can  f  4  were
performed with the IEDB Analysis Resource program. Altogether, 38 DR-binding motifs, 6
DP-binding motifs and 7 DQ-binding motifs in Can f 4 were predicted. When assessing the
correlation of the predictions and the experimentally identified epitope regions, 38 out of 51
predicted motifs were experimentally confirmed, i.e. the prediction specificity was 75% (III,
Fig. 3). In addition, eight core sequences were experimentally discovered outside the HLA
binding predictions, indicating a prediction sensitivity of 84%. Importantly, most (37/51;
73%)  of  the  predicted  HLA-binding  sites  were  found  to  be  contained  in  the  four  most
stimulatory epitope regions of Can f 4, each of them containing at least four distinct binding
motifs  (III,  Fig.  3),  suggesting  that  the  promiscuous  HLA-binding  capacity  is  linked  with
the antigenicity of Can f 4 epitope regions.
To experimentally validate the HLA binding predictions, the binding affinities of 15
selected  peptides  covering  the  immunodominant  epitope  regions  to  a  panel  of  prevalent
HLA-DR  molecules  were  measured.  In  line  with  the  predictions,  promiscuous  HLA
binding was observed, as three of the four regions contained peptides that were capable of
binding  to  a  minimum  of  three  different  HLA  class  II  alleles  with  a  moderate  to  high
affinity (III, Table II). Notably, the peptides aa 43-58 and 46-58 from the most antigenic
epitope  region  of  Can  f  4  bound  to  the  HLA  class  II  alleles  in  the  most  prevalent  way
(strong binding affinity to 5/6 and 4/6 HLA alleles tested, respectively; III, Table II).
5.4.3 Co-localization of epitopes in lipocalin allergens and human tear lipocalin
The  amino  acid  sequence  of  Can  f  4  was  aligned  with  the  sequences  of  other  lipocalin
allergens with previously mapped T cell epitopes (8,10,12,13) as well as with the sequence
of the human tear lipocalin to assess the degree of co-localization of the epitopes. Generally,
it was observed that there was high variability between the epitope regions (data not
shown).  However,  one  region  was  found  to  co-localize  with  all  of  these  proteins  (Fig.  3).
Interestingly, this epitope region partly overlaps with the first of the three structurally
conserved regions of lipocalin proteins, which is characterized by the signature motif
glycine-X-tryptophan (see 2.2.3). Despite the co-localization, the region was not considered
immunodominant with any of the proteins studied.
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Figure 3. Co-localization of the lipocalin T cell epitope cores (blue lines). The first structurally
conserved region of the lipocalins is indicated with a box. The signature motifs are shown in red.
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6 Discussion
6.1 ALLERGENICITY OF DOG LIPOCALIN ALLERGENS (I-II)
6.1.1 Suboptimal T cell recognition of lipocalin allergens by human T cells
Only a limited number of environmental proteins are allergenic,  i.e.  capable of inducing a
specific  Th2-deviated  CD4+  T  cell  response  and  the  subsequent  production  of  IgE-
antibodies by B cells in susceptible individuals (70). Therefore, it is conceivable that
allergens possess specific properties that contribute to the allergic sensitization mounted
against  these  agents.  As  reviewed  in  2.3.3,  most  of  the  significant  mammal-derived
respiratory allergens belong to the lipocalin family of proteins. The allergenicity of lipocalin
allergens has been proposed to be associated with their evolutionary relatedness with
human lipocalins (224). According to the hypothesis, the presence of endogenous lipocalins
in humans should have resulted in the elimination of strongly responding cells from the
lipocalin allergen-specific T cell repertoire. The allergic immune response would therefore
arise from the low-avidity interactions between the allergen and remaining T cells,  which
could predispose the immune response towards being Th2-dominated (129,225,226). The
theory is based on the uniform observations that PBMCs from clinically allergic subjects
proliferate very weakly upon stimulation with lipocalin allergens (9,10,13,227), and on the
observation that lipocalin allergen-specific T cell lines are capable of cross-recognizing
endogenous lipocalins (228).
The results from study I support this hypothesis. It was observed that the peptide p105-
120 containing an epitope of the dog lipocalin allergen Can f 1 is recognized suboptimally
by human T cells. A total of 14 heteroclitic APLs were identified that were able to induce T
cell proliferation at 10-30-fold lower concentrations than the natural peptide p105-120.
Suboptimal recognition of p105-120 was found not to be limited to the T cell clones alone,
as  it  was  also  demonstrated  with  polyclonal  TCLs  derived  from  the  peripheral  blood  of
dog-allergic subjects. Four out of five heteroclitic APLs (R110K, K113R, L115F and G116T)
were  more  frequently  capable  of  inducing  specific  TCLs  from  the  PBMCs  of  six  Can  f  1-
allergic subjects with heterogeneous HLA backgrounds than the natural peptide (II, Table
1). The total number of specific TCLs induced with one of the APLs, L115F, was statistically
significantly higher than that induced with p105–120 (19 TCLs vs. 4 TCLs, p=0.002).
Importantly, 13 of the 19 TCLs induced with L115F were cross-reactive with p105̄120
demonstrating that L115F could expand p105-120-reactive T cells more efficiently than the
natural peptide in vitro (13 TCLs vs. 4 TCLs, p=0.04). Since most of the L115F-induced TCLs
recognized p105-120 with a lower avidity, the increased frequency of p105̄120-reactive
TCLs may be explained by the enhanced capacity of L115F to activate low-avidity p105̄
120-specific T cells. Moreover, the heteroclitic activity of the APLs over p105-120 is likely to
be attributable to the improved TCR recognition rather than to the HLA binding, as the
HLA-binding affinities of p105-120 and the APLs were observed to be largely similar.
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The strength of TCR stimulation has been acknowledged as an important regulator of the
quality of the T cell response, with strong stimulation favoring Th1 differentiation and
weak stimulation leading to Th2 dominance (84,129,226). The exact mechanisms by which
the strength of TCR recognition drives the phenotypic differentiation of the cells are not
clear, but it has been associated with changes in the levels of endogenously produced IL-4
that is regulated by several different TCR downstream signaling routes (131,229,230).
Although the phenotypic differences between the TCLs induced with p105-120 and its
analogues were minimal, the APLs were observed to exhibit some immunomodulatory
capacity, as the most stimulatory L115F, for instance, induced a balanced Th0-type response
but  the  less  stimulatory APL L114I  induced Th2-biased responses  (I,  Table  3).  Shaping of
the allergic T cell response in vitro has  also  been  demonstrated  previously  with  the
heteroclitic APLs of the immunodominant epitope of the cow lipocalin allergen Bos d 2. The
analogues  of  Bos  d  2  have  been  found  to  induce  greater  Th1/Th2  ratios  in  the  cytokine
secretion by Bos  d 2-specific  T  cell  clones  than the  natural  epitope (231).  Moreover,  TCLs
induced from multiple patients with one of the analogues exhibited a more Th1-deviated
phenotype than those induced with the natural epitope (232). Collectively, both the
previous  as  well  as  the  current  results  indicate  that  the  poor  antigen recognition can be  a
factor promoting weak Th2-deviated T cell responses against lipocalin allergens.
6.1.2 Human CD4+ T cell responses to the dog allergen Can f 1 and its human homologue
tear lipocalin resemble each other
The identification of heteroclitic APLs, and thereby the suboptimal T cell recognition of the
natural epitopes of lipocalin allergens, is not a unique feature of these proteins. Several self
antigens,  such  as  myelin  basic  protein  (233)  and  proteolipid  protein  (234),  have  been
demonstrated to be recognized suboptimally by human T cells. Instead, this feature does
not  appear  to  be  a  characteristic  of  true  foreign  antigens,  such  as  influenza  virus
hemagglutinin (HA) (235).  Lipocalin allergens also resemble self  proteins in terms of their
amino  acid  sequence  (see  2.2.3).  For  example,  Can  f  1  and  the  human  tear  lipocalin  (TL)
share  a  sequence  identity  of  about  60%.  On  the  basis  of  sequence  homology,  lipocalin
allergens, proteins of exogenous origin, may be immunologically close to endogenous
antigens. In other words, they may exist at the borderline of self and non-self.
This idea was further examined in study II in a setting where the antigenicity of Can f 1 on
CD4+ T cells was compared in vitro with that of tear lipocalin, a homologous self protein
and influenza HA,  an exogenous microbial  antigen.  Based on the  estimation by the  split-
well method, the frequency of Can f 1 peptide-specific CD4+ T cells proved to be low, at the
level of 1 per 106 CD4+ T cells. Previous estimations on the frequency of lipocalin allergen-
specific  CD4+  T  cells,  analyzed  with  the  same  method,  have  been  in  the  same  range
(83,228,236). It is possible that the in vitro -protocol used in the current study may
underestimate the antigen-specific CD4+ T cell frequencies to some extent. However, only
slightly higher frequencies of lipocalin allergen-specific CD4+ T cells have been reported in
a study utilizing another approach, the HLA class II tetramer technique (236). Importantly,
in the study II, the frequency of Can f 1-specific CD4+ TCLs was observed to be very close
to that of the CD4+ TCLs specific to TL. This contrasted clearly with the frequency of the
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CD4+ TCLs specific to the influenza hemagglutinin, known to contain a potent epitope
(216). In accordance with the frequency data, the strength of the in vitro proliferative
responses of peptide-specific TCLs did not differ between Can f 1 and TL in the comparison
of allergic and nonallergic subject groups but they were clearly weaker than the responses
of  TCLs  specific  to  the  HA  peptide  (II,  Fig.  2A).  A  further  analysis  suggested  that  the
phenomenon was attributable to the low functional TCR avidity of the lipocalin peptide-
specific TCLs in comparison to those specific to HA (II, Fig. 2A). The HLA class II binding
affinity or the peptides did not appear to be able to explain the results, as it was found to be
very similar for all of the antigens examined in the study (II, Fig. 5), and the distribution of
HLA class II alleles did not differ between allergic and healthy subjects (II, Table S1). In line
with the  current  results,  a  study analyzing Can f  1-specific  CD4+ T cell  proliferation with
the CFSE dilution assay revealed that the proliferative response of Can f 1-reactive memory
CD4+  T  cells  of  allergic  subjects  was  clearly  weaker  than  that  for  streptokinase  (SK)  and
purified protein derivative (PPD), antigens of microbial origin (83). Several other studies
have also reported that T cell responses specific to autoantigens generally exhibit lower
TCR avidity than those specific for the exogenous microbial antigens, including influenza
HA (233,237-239).
The Can f 1 and TL peptide-specific TCLs also resembled each other phenotypically. The
production  of  the  Th2  cytokines  IL-4  and  IL-5  predominated  with  both  Can  f  1  and  TL-
specific TCLs, whereas the HA-specific TCLs mostly produced the Th1 cytokine IFN- (II,
Fig.  3).  A similar  phenotypic  difference  was also  seen in  the  analysis  of  the  T cell  surface
markers, as a higher expression of CCR4 and a lower expression of CXCR3 by the Can f 1
and TL-specific  TCLs was observed in  comparison to  the  HA-specific  TCLs (II,  Fig.  4).  In
all, the functional avidities and phenotypic deviations of the lipocalin and HA peptide-
specific  TCLs  are  in  line  with  the  concept  that  low  TCR  avidity  favors  Th2-development
whereas high avidity promotes Th1-development, respectively (84,129,226).
6.1.3 The multiple layers of allergenicity
The  current  results  suggest  that  the  human  CD4+  T  cell  responses  to  Can  f  1  and  TL
resemble each other in a surprising manner, with Can f 1 appearing to be only slightly more
antigenic on human T cells than its self homologue in vitro. This observation is in line with
the findings  of  the  suboptimal  stimulatory capacity  of  Can f  1  (I).  This  feature  is  likely  to
affect the development of Th2-type immune response and could therefore be considered as
a factor promoting the allergenicity of Can f 1. However, as demonstrated with many other
allergens (see 2.2.2), it is probable that there are also other mechanisms associated with Can
f 1 and other lipocalins that contribute to their allergenic capacity (240).
These mechanisms include at least physical properties, i.e. the efficient dispersion
capability of lipocalins from animal dander and excretions in the environment and inhaled
air (5). Although the ability to promote the activation of the innate immune system has
been postulated as a mechanism of allergenicity for a wide and diverse group of allergen
proteins (76,243,244), it has remained somewhat unclear with lipocalin allergens (245).
Instead, the adjuvantic effect provided by bacterial lipopolysaccharide (LPS), a substance
commonly coexisting with animal dander, has been shown to favor the Th2 differentiation
of the adaptive immune cells (241,242). Another factor possibly promoting the allergenicity
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of  lipocalins  may  be  enzymatic  activity.  For  example,  the  human  tear  lipocalin  has  been
reported  to  function  as  an  endonuclease  (246)  and  a  cysteine  protease  inhibitor  (247).  In
view of its structural similarity with Can f 1, the enzymatic activity could also be a property
of Can f 1 (248),  although this motif is only partially conserved in the allergen. Moreover,
ligation to the mannose receptor (MR) on dendritic cells by the carbohydrate structures of
glycoprotein allergens has been shown to play a role in the induction of Th2 cells (76,249),
and might also be involved in the allergenicity of Can f 1, which is a glycosylated protein.
Finally, one interesting characteristic of lipocalins in terms of their allergenicity not
examined in detail here is their lipid binding capacity. Bioactive lipid cargo could enhance
the allergenic response via Toll-like receptors (TLR) or CD1 pathways (250,251).
Considering all these factors, the basis for the allergenicity of lipocalins is most probably a
multidimensional phenomenon with many aspects yet to be unraveled.
6.2 T CELL EPITOPES OF CAN F 4 (III)
6.2.1 The region aa 43-67 of Can f 4 is highly stimulatory on human CD4+ T cells
Detailed characterization of allergen epitopes is a premise for understanding the allergic
sensitization process and for the development of better preparations for both the
diagnostics  and  the  immunotherapy  of  allergy.  The  epitopes  of  Can  f  4  were  found  to
cluster in several regions of the allergen (III, Table I). Four highly immunogenic epitope
regions (aa 13-31, 43-67, 91-127 and 124-148) were identified. On average, three and two
epitope regions were recognized by an allergic and a nonallergic subject, respectively. The
most frequently recognized region, aa 43-67, stimulated the Can f 4-specific TCLs in 90% of
the  allergic  subjects  tested.  The  significance  of  this  region  for  the  allergenicity  of  Can  f  4
was  further  emphasized  by  the  observation  that  three  of  the  allergic  subjects  reacted
exclusively to this epitope (III, Table I).
The T cell  epitopes of four other lipocalin allergens, Can f 1(8),  Bos d 2 (10),  Equ c 1 (12)
and Rat n 1 (13), have similarly been observed to be localized in specific regions along the
allergen sequences. Interestingly, when the sequences of Can f 4 and these allergens were
aligned, the first structurally conserved region of lipocalins containing the sequence motif
G-x-W  (252)  was  found  to  be  stimulatory  for  T  cells  in  all  of  these  allergens  (Fig.  3).  The
corresponding region of the human endogenous tear lipocalin was also shown to be
antigenic for human T cells (peptide pTL1 in study II).
The co-localization of  T  cell  epitopes  has  similarly  been reported within the  allergens  of
the pathogenesis-related (PR)-10 family of plant proteins such as birch (Bet v 1) (253), apple
(Mal d 1) (254), celery (Api g 1) (255) and hazelnut (Cor a 1) (256) allergens. In these
allergens, the co-localizing epitopes were observed to focus on the regions with a high level
of amino acid sequence homology. Consequently, T cells recognizing these regions also
showed a high degree of cross-reactivity (253). The T cell cross-reactivity of lipocalin
allergen  epitopes  appears  to  be  less  prominent,  probably  due  to  their  lower  sequence
identity  (generally  around  20-40%).  However,  it  is  noteworthy  that  a  few  TCLs  induced
with peptides from Can f 1 and TL, i.e. those exhibiting a sequence homology of about 60%,
demonstrated  cross-reactivity  with  their  counterparts  in  study  II  (Fig.  S2)  and  also  in  a
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previous study (228). As T cell cross-reactivity of endogenous and exogenous proteins has
also been reported in autoimmune diseases (257-259), it is conceivable that the homology of
self and non-self structures plays a role in the pathogenesis of immunological diseases.
6.2.2 The promiscuous HLA-binding of the T cell epitopes of Can f 4
In autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis or type 1 diabetes,
the disease susceptibility is strongly associated with certain HLA class II genes (260). In
allergic diseases, HLA-restriction elements have been revealed for example with the
ragweed  allergen  Amb  a  5  that  contains  a  single  T  cell  epitope  exclusively  presented  by
HLA-DRB11501/02 (261). Associations have also been reported with the mugwort allergen
Art v 1 (HLA-DRB1*01 and HLA-DRB1*16) (262) and the bee venom PLA2 (DRB1*0103/
DQB1*0501) (263). However, these cases represent a minority of allergens, and generally
multiple epitopes with multiple restriction elements are involved in the response.
The majority of the Can f 4-specific T cell responses were found to be restricted by HLA-
DR (III, Table E5). In line with this observation, the T cell responses to Timothy grass (264)
ragweed (265) and horse (266) allergens have also been observed to skew towards HLA-DR
restriction.  The  findings  are  not  surprising  since  HLA-DR  molecules  are  expressed  more
abundantly than -DP or -DQ molecules on professional APCs (267). Importantly, the T cell
response to each of the four dominant Can f 4 epitope regions identified was restricted by
at  least  two  different  types  of  HLA  molecules  (III,  Table  E5).  This  promiscuous  HLA
presentation was confirmed by the finding that epitope-containing peptides were
commonly observed to bind to several HLA-DR alleles with moderate to high affinity (III,
Table II). Moreover, the bioinformatically predicted HLA-binding motifs were found to
cluster  in  these  regions  (III,  Figure  3).  Of  special  interest,  the  most  stimulatory  Can  f  4
region,  aa  43-67,  was  predicted  to  contain  a  total  of  16  HLA-DR,  -DP  and  -DQ  binding
motifs (III, Fig. 3). Peptides covering this region also exhibited a high binding affinity to
most of the HLA alleles tested (see Table II). These data collectively suggest that the
capacity of peptides to bind to different HLA class II molecules is a factor associated the
immunodominance of Can f 4 epitopes. Promiscuous HLA binding has also been associated
with  the  immunodominance  of  the  epitopes  of  Timothy  grass  allergens  (264)  as  well  as
those of microbe-derived proteins (268,269).
6.2.3 Bioinformatic predictions of T cell epitopes of allergens
When  the  IEDB  analysis  of  the  HLA-binding  motifs  of  Can  f  4  was  compared  to  the
experimentally discovered Can f 4 epitope regions (III, Fig. 3), the predictive sensitivity of
75% was achieved. Previously, the coverage of bioinformatic predictions has been shown to
be lower, around 50% of the experimentally discovered epitopes (264,270). This can
partially be attributable to methodological differences between the studies. In addition, it
was  observed with Can f  4  that  17% of  the  experimentally  revealed epitope regions  were
not covered by the prediction algorithms. Based on these results, it appears that although
the algorithms could be useful in the selection of likely T cell  epitope candidates within a
protein, they may be insufficient to gather a comprehensive and detailed characterization of
allergen epitopes. Furthermore, the apparent inaccuracy of the bioinformatics approach to
predict T cell epitopes demonstrates that the HLA-binding capacity can not solely explain
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the antigenicity of an allergen epitope. Instead, other mechanisms are likely to be involved
in the process. These include at least the regulation of antigen processing in dendritic cells
that contributes to the epitope density on APCs (271,272).
6.3 DOG ALLERGEN-SPECIFIC T CELL RESPONSES IN INDIVIDUALS
WITH AND WITHOUT ALLERGY (II-III)
6.3.1 Can f 4-specific memory CD4+ T cells exist at higher frequencies in allergic subjects
in comparison to nonallergic subjects
Understanding the allergen-specific CD4+ T cell responses in both allergic and nonallergic
individuals is essential for elucidating the pathogenesis of allergy. Moreover, characterizing
the mechanisms of the natural, unharmful responses in healthy individuals can be helpful
in developing specific immunotherapeutic approaches. Therefore, the functional and
phenotypic properties of the T cell response to the dog lipocalin allergens Can f 1 and Can f
4 in allergic and healthy subjects were compared in studies II and III.
When the frequencies of allergen-specific CD4+ T cells were assessed in the PBMC
cultures  induced  with  the  Can  f  1  peptides  pC1-pC9,  no  significant  differences  were
observed  between  the  two  subject  groups  (II).  Instead,  an  eight-fold  higher  frequency  of
Can f 4-specific CD4+ T  cells  of  memory  origin  was  demonstrated  in  allergic  than  in
nonallergic subjects (III). These observations are in concordance with several other studies
in which the characterization of unpurified cell populations has yielded only marginal
differences  in  the  frequency  of  allergen-specific  CD4+  T  cells  between  allergic  and
nonallergic subjects (228,266,273,274). Instead, substantial differences in the frequency of
isolated antigen-specific memory (CD45RA–CD45RO+) CD4+ T cells between the diseased
and healthy subject groups have been reported in vitro and ex vivo in both allergic (83,275-
278) and autoimmune diseases (279,280). This discrepancy is likely to be attributable to the
activation and preferential expansion of naïve T cells in unpurified PBMC cultures in vitro,
as allergic and nonallergic subjects appear to harbor naïve allergen-specific CD4+ T cells at
comparable frequencies (275).
Further  characterization  of  the  allergen-specific  T  cell  responses  revealed  that  Can  f  4-
specific  T  cells  from  allergic  subjects  were  of  higher  functional  avidity  than  those  from
healthy subjects (III, Fig 1B). Based on the predominant IL-4 and IL-5 cytokine production
and the low expression of the surface marker CXCR3, the Can f 1 and Can f 4-specific T cell
lines  of  allergic  subjects  can  be  regarded  as  Th2-biased  (II,  Fig.  3;  III,  Fig.  2A  &  2B).  In
contrast, the Can f 4-specific memory CD4+ T cells of nonallergic subjects responded to
allergen stimulation with stronger IFN- and IL-10-biased cytokine production indicative
of a Th1/Tr1-deviated phenotype (III, Fig. 2A & 2B).
6.3.2 The expansion capacity of allergen-specific T cells in nonallergic subjects is limited
The exact mechanisms accounting for the frequency difference of allergen-specific memory
CD4+ T cells between allergic and healthy individuals are largely unclear. It is likely,
however, that they reflect the differential in vivo activation and expansion capacities of
allergen-specific T cells in allergic and nonallergic subjects in response to allergen
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challenge. It  is  known  that  T  cells  with  a  strong  TCR  affinity  for  their  antigen  can
outcompete lower affinity cells and begin to dominate the immune response under antigen
stimulation (281-283). The observation that Can f 4-specific memory T cell responses in the
allergic subjects exhibited higher functional avidity (III, Fig. 1B) is in line with this concept.
Moreover,  it  was  commonly  found  that  several  individual  TCLs  from  an  allergic  subject
recognized  exactly  the  same  epitope  regions  of  Can  f  4  (III,  Table  E4).  Although  not
analyzed at the TCR sequence level, this observation suggests that they likely represent
clonal expansions of the same allergen-specific precursor. Together with the higher
expression  of  CD25  on  the  Can  f  4-specific  TCLs  of  allergic  subjects  (III,  Fig.  2C),  these
findings indicate that the T cells of allergic subjects exhibit more effective in vivo activation
capacity than the Can f 4-specific T cells of nonallergic individuals.
Several factors can contribute to the restricted capacity of nonallergic subjects to generate
Th2-type responses to allergens. One possibility could be that allergic and nonallergic
subjects  differ  in  terms  of  their  naïve  T  cell  repertoires.  In  support  of  this  view,  a  study
characterizing the T cell repertoires of allergic and nonallergic subjects specific to an
immunodominant epitope of the cow lipocalin allergen, Bos d 2, reported functional and
phenotypic differences not only in the allergen-specific memory T cell repertoire but also in
the naïve repertoire (275). As the composition of the naïve antigen-specific T cell repertoire
has  been  demonstrated  to  directly  affect  the  diversity  and  quality  of  a  primary  CD4+
antigen-specific response (284,285), differential naïve repertoires could theoretically
provide one explanation for the differential responses between allergic and nonallergic
subjects.
As the Can f 4-specific responses of nonallergic subjects were generally very weak, low in
terms of  their  functional  avidity  and only  weakly Th1 or  Tr1-polarized,  it  is  possible  that
they are not bona fide allergen-specific T cells, but rather represent a marginally cross-
reactive population primed in vivo with an unrelated, high-affinity antigen, for example, a
microbial antigen. This hypothesis is supported by a recent report that demonstrated the
existence  of  memory-phenotype  CD4+  T  cells  specific  to  numerous  foreign  and
autoantigens without any preceding exposure. The cells displayed cross-reactivity with
homologous epitopes from environmental antigens (286). The reported frequencies of these
cross-reactive  CD4+  T  cells  in  the  peripheral  blood  were  in  the  same  range  as  those
observed with Can f 1 (II) and Can f 4 (III) in nonallergic subjects.
Another mechanism affecting the differences in the T cell responses between subjects with
and without allergy may be the differential recognition of allergen epitopes. For example, it
has been reported that the cat allergen Fel d 1 contains tolerogenic DR7-restricted epitopes
associated with IL-10 and IFN- production in PBMC cultures. Recognition of those
epitopes could provide a protective effect in subjects expressing the DR7 allele (287).
However, when a comparison was made of the recognition of dog lipocalin allergen
epitopes by the specific TCLs of allergic and nonallergic subjects in study II,  it  was found
that  the  same  individual  Can  f  1  peptides  were  recognized  by  the  TCLs  of  both  subject
groups (II, Fig. 1B). The Can f 1 peptide pC4 was found to be the peptide most frequently
recognized by the  individuals  in  both of  the  groups (II,  Fig.  1B).  In  study III,  the  Can f  4
epitope regions recognized by TCLs from allergic subjects were also observed to stimulate
Can f 4-specific TCLs obtained from subjects without allergy (III,  Table I).  With respect to
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the T cell phenotype, no polarization was observed in relation to the epitope specificity of
the  Can  f  1  and  Can  f  4-specific  TCLs  (data  not  shown).  Collectively,  the  observations
suggest that the T cell epitope recognition patterns are unlikely to determine the
susceptibility to develop allergic sensitization to Can f 1 or Can f 4.  Similar findings have
also been reported with many other allergens (163,288,289).
There is also evidence that active peripheral regulatory mechanisms, especially regulatory
T cells, would play a role in the suppression of harmful allergen-specific T cell responses in
nonallergic  individuals.  In  one  study  in  which  the  T  cell  responses  specific  to  the  birch
allergen Bet v 1 and house dust mite allergen Der p 1 were compared between allergic and
nonallergic subjects, it was observed that the healthy subjects harbored significantly higher
frequencies  of  IL-10-secreting  Tr1  cells  than  allergen-specific  Th2-type  cells,  whereas  the
situation with allergic subjects was the opposite (160). Another study indicated that the
suppressive function of atopic subjects’ CD4+CD25+ regulatory T cells is compromised
(290).  The induction of  regulatory T cells  appears  to  be  one of  the  central  mechanisms in
allergen-specific immunotherapy (see 2.5.5). The finding that IL-10 was produced
predominantly by the Can f 4-specific memory TCLs of nonallergic individuals (III, Fig. 2A)
suggests that regulatory T cells (Tr1) may also be involved in the development of tolerance
to lipocalin allergens, although opposite results have also been presented (83).
In conclusion, possible mechanisms differentiating the allergen-specific CD4+ T cell
responses  in  allergic  and  nonallergic  subjects  include  the  composition  of  naïve  T  cell
repertoires, the function of regulatory T cells and HLA associations of allergen epitopes.
Since  also  many  other  cell  types,  for  example  those  of  innate  immunity  (291),  appear  to
function differently between individuals with and without allergy, it is evident that the
allergenic polarization of the T cell response is the overall result of a complex interplay
between the cells of the immunological network.
6.4 IMMUNOTHERAPEUTIC POTENTIAL OF CAN F 1 AND CAN F 4
EPITOPE-CONTAINING PEPTIDES (I, III)
6.4.1 Can f 446-64 – a candidate peptide for dog allergen-specific peptide immunotherapy?
The  principle  of  peptide  immunotherapy  is  the  use  of  preparations  composed  of  linear
peptides containing the T cell epitopes of a native allergen, which is an attractive option for
conventional allergen immunotherapy alternative using crude allergen extracts due to the
reduced risk of IgE-mediated adverse systemic reactions (292,293). The administration of
peptides containing a single or a few T cell epitopes of an allergen has been demonstrated
to induce hyporeactivity to the entire protein in numerous murine experiments
(181,182,193,294) and clinical trials (187,190), probably by linked epitope suppression (193)
via the induction of T cells with regulatory or immunosuppressive function
(187,190,193,294).
For the development of population-wide peptide immunotherapy, the identification of
promiscuous allergen epitopes, i.e. those with a capacity to bind to a variety of commonly
expressed HLA class II molecules, are of special interest. In study III, the subjects included
in the Can f 4 epitope mapping were found to express the most common HLA-DRB1 alleles
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in the Finnish population (295), with the exception of DRB1*0301. The T cells of 90% of
these  subjects  were  capable  of  recognizing  the  region  aa  43-67  of  Can  f  4.  Moreover,  the
region was predicted to contain a total of 14 different HLA class II binding motifs (III, Fig.
3). Based on these results, the peptide Can f 446-64 containing the minimal core of the region
(III, Fig. 3) could be considered as a potential candidate for Can f 4-specific peptide
immunotherapy.
However, it is noteworthy that the individual reactivity to allergen epitopes can vary
considerably, not only as a result of differential HLA class II restrictions of epitopes but also
due to mechanisms associated with antigen processing and presentation, as discussed
above  (see  6.2.3).  For  example,  it  was  observed  in  study  III  that  individuals  sharing  the
same  HLA  class  II  genotype,  e.g.  the  dog-allergic  subjects  A-2,  A-5  and  A-8
(DRB1*0101/1501, DQB1*0501/0602; III, Tables 1 and E1), displayed variability in their
epitope recognition patterns. In view of this heterogenity of the T cell response, the use of a
single  peptide,  pCan  f  446-64, containing the immunodominant epitope may be an
insufficient approach for designing peptide immunotherapy to Can f 4 allergy. Instead,
using a combination of several epitope-containing peptides could be functional. In support
of  this  view,  it  has  been  shown  that  a  mixture  of  six  peptides  of  Japanese  cedar  pollen
allergens Cry j 1 and Cry j 2 stimulated human PBMCs in vitro more efficiently than a single
epitope-containing peptide (296). As an average of 2.6 of the four immunodominant Can f 4
epitope regions  were  recognized per  allergic  subject,  a  pool  of  peptides  derived from the
most antigenic regions of Can f 4 (aa 13-31, 43-67, 91-127 and 124-148) could be considered
as an ideal combination for the induction of tolerance in the vast majority of Can f 4-allergic
individuals.
Another problem linked with the treatment of dog allergy with Can f 4 preparations is
that only 35-60% of dog allergic subjects are sensitized to the allergen. Moreover, most dog
allergic subjects are sensitized to several of the six known dog allergens, most commonly to
Can f 1 (63) or Can f 5 (69). Only a minority of the subjects reacts exclusively to Can f 4 (65).
Therefore, it is reasonable to assume that the treatment of dog allergy with Can f 4-derived
peptides alone is an inefficient approach. Instead, a more feasible option might be to select
cocktail of immunodominant T cell epitopes from the most commonly recognized dog
allergens. Another option could be the generation of a patient-tailored immunotherapy
vaccine based on the IgE reactivity profiling of an individual by allergen microarrays. This
would allow the precise identification of the disease eliciting allergens (297).
6.4.2 Therapeutic potential of altered peptide ligands
Hypothetically, the use of altered peptide ligands could be another way to further develop
the efficacy of peptide-based immunotherapy. APLs that exhibit cross-reactivity with the T
cells specific to the natural T cell epitope of an allergen and which mediate tolerogenic or
Th1-deviating outcomes would be of special interest (298). Previously, a heteroclitic
analogue of the peptide containing the immunodominant epitope of the cow lipocalin
allergen Bos d 2 was observed to induce apoptosis, hyporesponsiveness and increased
Th1/Th2  cytokine  ratios  in  the  allergen-specific  T  cell  clones in vitro.  Similar  effects  have
also been reported with the analogues of the house dust mite Der p 1 (299,300) or the bee
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venom PLA2 (301) allergen epitopes. In study I, the APLs of the Can f 1 peptide p105–120
exhibited a capacity to functionally and qualitatively modify the T cell response (I, Tables 2
&  3).  Two  of  the  analogues  were  observed  to  induce  a  Th2-deviated  response  with  IL-5
production predominating, whereas the other three induced a more balanced Th0-type
response. Cross-recognition of the natural epitope was observed with the majority of the
TCLs  induced  with  the  APLs.  In  particular,  the  analogue  L115F  could  be  considered
therapeutically potential, as it was capable of inducing strong T cell responses that were
highly cross-reactive with the peptide containing the natural epitope.
Despite these promising preclinical studies, however, evidence for the safety and efficacy
of altered peptide ligands in a clinical setting are lacking. Based on the reports from clinical
trials of autoimmune diseases (211,212), the major problem associated with the APL-
mediated immunotherapy appears to be the unpredictability of the subsequent T cell
response. For example, it has been shown that an antagonistic APL for a T cell clone in vitro
may act as an agonist for another autoreactive T cell in vivo (302). Thus, taking into account
the broadness of the human T cell repertoire, the development of APL-based
immunotherapy may be hampered by the risk that they may evoke harmful cross-reactive
responses (198,303).
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7 Conclusions
This study aimed to dissect the mechanisms behind allergy against the dog lipocalin
allergens Can f 1 and Can f 4 by comparing CD4+ T cell responses against them in allergic
and nonallergic individuals. In addition, T cell epitopes within Can f 1 and Can f 4 were
characterized and the potential of selected epitopes for peptide immunotherapy of dog
allergy was evaluated.
Can f 1 was found to be weakly antigenic on human CD4+ T cells in vitro, as the cellular
responses  to  Can  f  1  resembled  those  to  the  endogenous  homologue,  tear  lipocalin.  The
responses clearly contrasted with those to a microbial antigen, influenza hemagglutinin.
The weak and Th2-deviated T cell responses against lipocalin allergens may be attributable
to the suboptimal recognition of their T cell epitopes. This was demonstrated here by the
identification of several heteroclitic APLs for the Can f 1 epitope-containing peptide p105-
120. The basis for the low antigenicity and suboptimal recognition of dog lipocalin allergens
by  human  T  cells  may  reside  in  their  structural  resemblance  with  self  antigens.  These
features can affect the development of a Th2-type immune response and could therefore be
considered as a factor promoting the allergenicity of Can f 1.
Dog lipocalin allergen-specific CD4+ T cell responses between allergic and nonallergic
individuals differ both functionally and phenotypically. Importantly, although allergen-
specific memory CD4+ T cells exist in both allergic and nonallergic subjects, their frequency
appears  to  be  lower  in  nonallergic  subjects  in  comparison  to  allergic  subjects.  Here,  an
eight-fold  difference  was  observed  in  the  frequency  of  Can  f  4-specific  memory  CD4+  T
cells between these subject groups. Active peripheral regulation is one possible mechanism
accounting for the phenomenon.
The binding capacity of Can f 4 epitope-containing peptides to a variety of HLA class II
molecules proved to play a major role in their capacity to induce T cell responses in vivo. In
therapeutic terms, an interesting target for further investigations would be the 19-mer
peptide Can f 446-64 containing the core sequence of the most immunogenic Can f 4 epitope
region. This peptide was found to contain multiple HLA class II-binding motifs and it was
recognized by the memory CD4+ T cells of 90% of the allergic subjects.
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Prospects for Allergen Immunotherapy
The aim of this study was to analyze 
human CD4+ T cell responses to the 
dog lipocalin allergens Can f 1 and 
Can f 4 in individuals with and with-
out dog allergy. 
In general, these allergens were 
found to be only weakly stimulatory 
on human T cells. However, substan-
tial differences were observed in 
the allergen specific memory CD4+ T 
cells between the allergic and nonal-
lergic subjects.
Importantly, a peptide derived from 
the Can f 4 allergen, Can f 446-64, was 
found to be immunodominant and 
could be considered as a candidate 
for the development of peptide im-
munotherapy of dog allergy. 
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